APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of Actomyosin by Uzureau, Sophie et al.
RESEARCH OUTPUTS / RÉSULTATS DE RECHERCHE
Author(s) - Auteur(s) :
Publication date - Date de publication :
Permanent link - Permalien :
Rights / License - Licence de droit d’auteur :
Bibliothèque Universitaire Moretus Plantin
Institutional Repository - Research Portal
Dépôt Institutionnel - Portail de la Recherche
researchportal.unamur.be
APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with
APOL3 Control of Actomyosin
Uzureau, Sophie; Lecordier, Laurence; Uzureau, Pierrick; Hennig, Dorle; Graversen, Jonas
H; Homblé, Fabrice; Mfutu, Pepe Ekulu; Oliveira Arcolino, Fanny; Ramos, Ana Raquel; La
Rovere, Rita M; Luyten, Tomas; Vermeersch, Marjorie; Tebabi, Patricia; Dieu, Marc; Cuypers,
Bart; Deborggraeve, Stijn; Rabant, Marion; Legendre, Christophe; Moestrup, Søren K;
Levtchenko, Elena; Bultynck, Geert; Erneux, Christophe; Pérez-Morga, David; Pays, Etienne
Published in:
Cell Reports
DOI:
10.1016/j.celrep.2020.02.064
Publication date:
2020
Document Version
Publisher's PDF, also known as Version of record
Link to publication
Citation for pulished version (HARVARD):
Uzureau, S, Lecordier, L, Uzureau, P, Hennig, D, Graversen, JH, Homblé, F, Mfutu, PE, Oliveira Arcolino, F,
Ramos, AR, La Rovere, RM, Luyten, T, Vermeersch, M, Tebabi, P, Dieu, M, Cuypers, B, Deborggraeve, S,
Rabant, M, Legendre, C, Moestrup, SK, Levtchenko, E, Bultynck, G, Erneux, C, Pérez-Morga, D & Pays, E
2020, 'APOL1 C-Terminal Variants May Trigger Kidney Disease through Interference with APOL3 Control of
Actomyosin', Cell Reports, vol. 30, no. 11, pp. 3821-3836.e13. https://doi.org/10.1016/j.celrep.2020.02.064
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            • Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            • You may not further distribute the material or use it for any profit-making activity or commercial gain
            • You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 23. Jun. 2020
ArticleAPOL1 C-Terminal Variants May Trigger Kidney
Disease through Interference with APOL3 Control of
ActomyosinGraphical AbstractNC
N
CPI(4)P
Golgi
APOL1 APOL3
PI4KB
APOL1NC
SRA
APOL1NC
Human immunity to T. rhodesiense
Wild-type
APOL1
C-terminal
APOL1 variants
Se
cr
ete
dA
PO
L1
in
hu
ma
ns
er
um
Trypanosoma
brucei
Trypanosoma
rhodesiense
C
SRA
N APOL1
Trypanosoma
rhodesiense
Int
ra
ce
llu
lar
AP
OL
1
in
kid
ne
yp
od
oc
yte
s
(PI(4)P)
APOL3
Golgi
PI4KB
N
C
APOL1
C
N
Kidney disease
Actomyosin changesHighlightsd C-terminal helix alteration unfolds APOL1, increasing APOL1
interaction with APOL3
d APOL3 binds to NCS-1, promoting NCS-1-PI4KB interaction
and PI4KB activation
d C-terminal APOL1 variants interfere with APOL3-NCS-1
interaction, inactivating PI4KB
d PI4KB inactivation occurs in podocytes from kidney disease
patients with APOL1 variantsUzureau et al., 2020, Cell Reports 30, 3821–3836
March 17, 2020 ª 2020 The Author(s).
https://doi.org/10.1016/j.celrep.2020.02.064Authors
Sophie Uzureau, Laurence Lecordier,
Pierrick Uzureau, ..., Christophe Erneux,
David Pe´rez-Morga, Etienne Pays
Correspondence
epays@ulb.ac.be
In Brief
Uzureau et al. propose a molecular
explanation for the linkage between
resistance to sleeping sickness and high
risk of kidney disease in African
individuals expressing APOL1 variants.
These variants resist neutralization by
T. rhodesiense SRA and kill the parasite,
but they also indirectly trigger podocyte
actomyosin reorganization through
interaction with APOL3, inactivating the
NCS-1-PI4KB complex.
Cell Reports
ArticleAPOL1 C-Terminal Variants May Trigger
Kidney Disease through Interference
with APOL3 Control of Actomyosin
Sophie Uzureau,1 Laurence Lecordier,1 Pierrick Uzureau,2 Dorle Hennig,3 Jonas H. Graversen,3 Fabrice Homble´,4
Pepe Ekulu Mfutu,5 Fanny Oliveira Arcolino,5 Ana Raquel Ramos,6 Rita M. La Rovere,7 Tomas Luyten,7
Marjorie Vermeersch,8 Patricia Tebabi,1 Marc Dieu,9 Bart Cuypers,10,11 Stijn Deborggraeve,10 Marion Rabant,12
Christophe Legendre,13 Søren K. Moestrup,3,14 Elena Levtchenko,5 Geert Bultynck,7 Christophe Erneux,6
David Pe´rez-Morga,1,8 and Etienne Pays1,15,*
1Laboratory of Molecular Parasitology, IBMM, Universite´ Libre de Bruxelles, 6041 Gosselies, Belgium
2Laboratory of Experimental Medicine (ULB222), CHU Charleroi, Universite´ Libre de Bruxelles, Montigny le Tilleul, Belgium
3Department of Molecular Medicine, Cancer and Inflammation Research, University of Southern Denmark, 5000 Odense C, Denmark
4Laboratory of Structure and Function of Biological Membranes, Universite´ Libre de Bruxelles, 1050 Brussels, Belgium
5Pediatric Nephrology, University Hospital Leuven, 3000 Leuven, Belgium
6Institute of Interdisciplinary Research in Human and Molecular Biology, Campus Erasme, Universite´ Libre de Bruxelles, 1070 Brussels,
Belgium
7Laboratory of Molecular and Cellular Signalling, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
8Center for Microscopy and Molecular Imaging (CMMI), Universite´ Libre de Bruxelles, 6041 Gosselies, Belgium
9URBC-Narilis, University of Namur, 5000 Namur, Belgium
10Biomedical Sciences Department, Institute of Tropical Medicine, 2000 Antwerpen, Belgium
11Adrem Data Lab, Department of Mathematics and Computer Science, University of Antwerp, 2000 Antwerpen, Belgium
12Adult Nephrology-Transplantation Department, Paris Hospitals and Paris Descartes University, 75006 Paris, France
13Pathology Department, Paris Hospitals and Paris Descartes University, 75006 Paris, France
14Department of Biomedicine, University of Aarhus, 8000 Aarhus, Denmark
15Lead Contact
*Correspondence: epays@ulb.ac.be
https://doi.org/10.1016/j.celrep.2020.02.064SUMMARY
The C-terminal variants G1 and G2 of apolipoprotein
L1 (APOL1) confer human resistance to the sleeping
sickness parasite Trypanosoma rhodesiense, but
they also increase the risk of kidney disease. APOL1
and APOL3 are death-promoting proteins that are
partially associated with the endoplasmic reticulum
and Golgi membranes. We report that in podocytes,
either APOL1 C-terminal helix truncation (APOL1D)
or APOL3 deletion (APOL3KO) induces similar acto-
myosin reorganization linked to the inhibition of phos-
phatidylinositol-4-phosphate [PI(4)P] synthesis by the
Golgi PI(4)-kinase IIIB (PI4KB). Both APOL1 and
APOL3 can formK+ channels, but only APOL3 exhibits
Ca2+-dependent binding of high affinity to neuronal
calcium sensor-1 (NCS-1), promoting NCS-1-PI4KB
interaction and stimulating PI4KB activity. Alteration
of the APOL1 C-terminal helix triggers APOL1 unfold-
ing and increased binding to APOL3, affecting
APOL3-NCS-1 interaction. Since the podocytes of
G1 and G2 patients exhibit an APOL1D or
APOL3KO-like phenotype, APOL1 C-terminal variants
may induce kidneydisease bypreventing APOL3 from
activating PI4KB, with consecutive actomyosin reor-
ganization of podocytes.Cell R
This is an open access article under the CC BY-NINTRODUCTION
Like human resistance to malaria is associated with inherited
sickle cell anemia, innate immunity to sleeping sickness is genet-
ically linked to chronic kidney disease (CKD) (Genovese et al.,
2010). This unexpected connection involves apolipoprotein L1
(APOL1), a protein found only in primates, which belongs to a
family of apoptotic proteins involved in cell death induced by viral
stimuli (Nichols et al., 2015; Uzureau et al., 2016; Vanhollebeke
and Pays, 2006). APOL1 is the only family member containing
an N-terminal signal peptide for secretion, and it is also the
only member with a clearly identified function. The secreted frac-
tion of APOL1 is the trypanolytic factor of human serum, able to
kill different subspecies of the African parasite Trypanosoma
brucei, but not the sleeping sickness agents T. b. rhodesiense
and T. b. gambiense (Pays et al., 2014; Vanhamme et al.,
2003). APOL1 is a pore-forming protein requiring acidic pH for
insertion into membranes and exhibiting cation channel activity
at neutral pH (Pe´rez-Morga et al., 2005; Thomson and Finkel-
stein, 2015) (APOL1 structure in Figure 1A). Trypanolytic activity
results from the induction of an apoptotic-like process in the
parasite following the intracellular transfer of APOL1-containing
endosomal membranes to the mitochondrion (Vanwalleghem
et al., 2015). T. b. rhodesiense neutralizes the toxicity of
APOL1 through the interaction of its serum resistance-associ-
ated (SRA) protein with the C-terminal leucine zipper (LZ) helix
of APOL1 (SRA-interacting domain [SRID] in Figure 1A) (Lecor-
dier et al., 2009; Pays et al., 2014; Vanhamme et al., 2003). Theeports 30, 3821–3836, March 17, 2020 ª 2020 The Author(s). 3821
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Figure 1. APOLs Are Membrane-Associated Proteins Involved in Poly(I:C)-Induced Podocyte Death
(A) APOL1 domains and mutations relevant for the study. SP, signal peptides (amino acids [aa] 1–27 and 28–53), PFD, pore-forming domain (aa 60–235), MAD,
membrane-addressing domain (aa 238–304), hinge (aa 305–339), SRID, SRA-interacting domain (aa 340–398), HC/LZ 1/2, pairs of associated hydrophobic
cluster and leucine zipper (aa 79–88/100–122 and 343–354/368–392), SID1/2, smallest interacting domains defined by Y2H interactions with the indicated bait
sequences (aa 78–121 and 346–390).
(B) APOLs immunodetection in total extracts from cells treated or not with poly(I:C). The arrows point to APOL3, located under a non-specific band. The bottom
panel shows the immunodetection of endogenous V5- or TriFLAG-tagged APOL3 in the relevant cell lines. Actin immunodetection serves as a loading control.
(C) Poly(I:C)-induced cell death in the different podocyte lines (error bars, SDs). See Figure S1 for additional data. WT, n = 11; 1KO, n = 7; 1Dhet, n = 7; 1Dhom,
n = 10; 3KO, n = 5; 1+3KO, n = 5; 2KO, n = 3; WT3V5, n = 6; 1Dhom3V5, n = 6.
(D) Immunodetection of recombinant APOLs (0.5 mg/mL) association with various lipids spotted on membrane strips. LPA, lysophosphatidic acid; LPC, lyso-
phosphocholine; PI, phosphatidylinositol; PE, phosphatidylethanolamine; PC, phosphatidylcholine; S1p, sphingosine-1-phosphate; PA, phosphatidic acid; PS,
phosphatidylserine; TG, triglyceride; DAG, diacylglycerol; PG, phosphatidylglycerol; CL, cardiolipin; Chol, cholesterol; SM, sphingomyelin. Blank, no lipid.
(E) Distribution of APOLs in cellular extracts from poly(I:C)-treated APOL3FLAG or APOL1Dhet podocytes, fractionated as indicated. Anti-FLAG antibodies were
used to detect APOL3. Calnexin and Golgin97 are representative ER transmembrane and peripheral trans-Golgi membranemarkers, which become soluble with,
respectively, 0.1% NP-40 (N) and carbonate pH 10 (C). The loading of ‘‘s’’ lanes corresponds to half that of ‘‘p’’ lanes.
(F) Distribution of APOLs in phosphatidylcholine liposomes containing or not containing 10% PI(4)P, following centrifugation at 10,000 3 g. S, supernatant;
p, pellet; equal amounts of initial material.naturally occurring APOL1 variants G1 andG2 contain mutations
in the C-terminal LZ, which affect the LZ structure and binding of
SRA and thus escape SRA-mediated neutralization (Genovese
et al., 2010; Sharma et al., 2016). Presumably due to their ability
to kill T. b. rhodesiense following SRA escape, these APOL1 var-
iants are frequently found in African populations (Genovese
et al., 2010). Unfortunately, the G1 and G2 variants also cause
kidney disease (KD) through an unclear mechanism involving
perturbation of podocyte vesicular traffic (Genovese et al.,3822 Cell Reports 30, 3821–3836, March 17, 20202010; Beckerman et al., 2017; Madhavan et al., 2017). Although
the secreted fraction of the APOL1 variants was presented as
responsible for the disease (Hayek et al., 2017), the variants pre-
sent intracellularly must be involved in podocyte dysfunction,
because circulating APOL1 levels do not correlate with the dis-
ease and because poor kidney allograft outcomes are associ-
ated with the APOL1 genotype of the transplanted kidney, but
not of the recipient patient (Beckerman and Susztak, 2018; Mad-
havan et al., 2017). Since some APOL1 transcripts encode
isoforms that cannot be secreted (Cheatham et al., 2018), at
least a fraction of intracellular APOL1 could exert a function in
the cytosol rather than within the secretory pathway.
Despite the clear involvement of APOL1 G1 and G2 in KD, in-
dividuals lacking APOL1 due to mutations in both APOL1 alleles
(Vanhollebeke et al., 2006) appear to be healthy (Johnstone et al.,
2012). Therefore, KD must result from negative effects of the
APOL1 variants rather than APOL1 inactivation. In accordance
with this conclusion, mice, which do not have the APOL1 gene,
exhibit KD following transgenic expression of human APOL1
C-terminal variants, and not wild-type (WT) APOL1 (Beckerman
et al., 2017).
Thus far, apart from the role of secreted APOL1 in innate im-
munity against African trypanosomes, the function of APOLs is
unknown. However, roles in the defense against pathogens are
likely (Smith and Malik, 2009; Vanhollebeke and Pays, 2006).
The expression of different APOLs, particularly APOL1 and
APOL3, is highly stimulated under inflammatory conditions, pri-
marily those activating the Toll-like receptor 3 (TLR3) such as
viral infection, which is mimicked in vitro by cell incubation with
poly(I:C) (Nichols et al., 2015; Uzureau et al., 2016). Concordant
with this observation, the risk of KD associated with the expres-
sion of C-terminal APOL1 variants is increased following viral
infection (Kasembeli et al., 2015; Kopp et al., 2017).
Various molecular mechanisms have been proposed to
explain the role of APOL1 C-terminal variants in podocyte
dysfunction (Beckerman et al., 2017; Bruggeman et al., 2016;
Cheng et al., 2015; Chun et al., 2019; Fu et al., 2017; Granado
et al., 2017; Hayek et al., 2017; Jha et al., 2019; Kruzel-Davila
et al., 2017; Kumar et al., 2019; Lan et al., 2014; Lee et al.,
2018; Madhavan et al., 2017; Mikulak et al., 2016; Okamoto
et al., 2018; Olabisi et al., 2016; O’Toole et al., 2018; Ryu et al.,
2019; Wen et al., 2018; Zhang et al., 2018), but the heteroge-
neous nature of these mechanisms, together with drawbacks
linked to non-specific toxicity due to APOL1 overexpression
(O’Toole et al., 2018), suggested that the fundamental explana-
tion remained undiscovered. Therefore, we undertook a detailed
analysis of several human podocyte cell lines whose genomes
were edited for the alteration of APOL1 and APOL3 genes, delib-
erately avoiding strategies of ectopic APOL expression. This
resulted in the identification of a function of APOLs in the regula-
tion of PI(4)P synthesis by PI4KB, hence in the control of actomy-
osin activity, which may explain the KD association of APOL1 G1
and G2.
RESULTS
APOL1 and APOL3 are Poly(I:C)-Induced Proteins
Partially Associated with Endoplasmic Reticulum (ER)
and Golgi Membranes
Incubation of podocytes with poly(I:C) strongly increased APOL1
and APOL3 expression (Figure 1B) and triggered cell death (WT
lanes in Figures 1C, S1A, and S1B). In contrast, poly(I:C) only
weakly increased APOL2 expression (Figure 1B).
APOL1 and APOL3 shared intranuclear and perinuclear distri-
butions, the latter involving important co-localization with ER and
trans-Golgi markers (Figures S2A–S2C). APOL3 co-localization
with the Golgi was higher than that of APOL1, but this differencewas erased by poly(I:C) (Figure S2C). Like APOL1, APOL3 and
APOL1 C-terminal variants exhibited in vitro binding to anionic
phospholipids, particularly phosphatidic acid, cardiolipin, and
several phosphoinositides (Figure 1D). In fractionated cellular
extracts, the APOL1 and APOL3 distribution resembled more
that of ER transmembranar calnexin than trans-Golgi mem-
brane-associated Golgin97, also with a minor cytosolic fraction
(Figure 1E). Finally, both APOLs exhibited increased binding to
liposomes that contained PI(4)P (Figure 1F).
We conclude that in podocytes, APOL1 and APOL3 are
poly(I:C)-induced phosphoinositide-binding proteins associ-
ating with ER and Golgi membranes.
Either APOL1 C-Terminal Helix Truncation or APOL3KO
Induces Actomyosin Reorganization
We used CRISPR-Cas9-mediated gene targeting to generate
different clones of APOL1KO, APOL3KO, and APOL1+3KO po-
docytes, together with clones encoding a C-terminally truncated
APOL1 (APOL1D, ending at V353, 36 kDa), either in only one
allele (APOL1Dhet) or both (APOL1Dhom) (Figures 1A, 1B, and
S3). We also generated APOL2KO cells as controls. Whole-
genome sequencing of representative clones did not reveal sig-
nificant off-target editing (Table S1). In addition, given that all of
the anti-APOL3 antibodies tested exhibited a non-specific inter-
action (Figure 1B, APOL3 top band), to enable specific APOL3
analysis, we usedCRISPR-Cas9 genome editing to generate po-
docyte cell lines expressing the V5 or TriFLAG tag in C-terminal
fusion with endogenous APOL3.
APOL1D shared the cellular fractionation pattern of APOL1
(Figure 1E). Furthermore, synthesis of APOL1D and tagged
APOL3was still stimulated by poly(I:C), suggesting no significant
alteration of gene expression due to APOL editing (Figure 1B).
In accordance with the involvement of APOLs in apoptosis
triggered by TLR3 activation (Uzureau et al., 2016), poly(I:C)-
induced cell death was reduced in both APOL1KO and
APOL3KO podocytes (Figures 1C, S1A, and S1B). In APOL1D
cell lines, poly(I:C)-induced cell death almost disappeared, sug-
gesting that APOL1D inhibits the death-promoting activity of
APOLs (Figures 1C, S1A, and S1B). In contrast, APOL2 was
not significantly involved in poly(I:C)-induced cell death (Fig-
ure 1C). Finally, cells with in situ-tagged APOL3 behaved like
WT podocytes, suggesting no influence of the tag on APOL3
function (Figure 1C).
We compared the observable cytological characteristics
of the different cell lines. The phenotypes of APOL1D and
APOL3KO cells, but not of APOL1KO, APOL1+3KO, and
APOL2KO cells, were characterized by changes in cell surface
area and perimeter (Figures 2A, S1C, and S1D), decrease in
cellular adherence to fibronectin (Figure 2B), increase in motility
linked to larger focal adhesion size (Figures 2C and S4A), and
loss of actin stress fibers associated with tropomyosin accumu-
lation in the perinuclear region (Figure 2D). In APOL1D cells, add-
back APOL1 expression reversed the increase in motility, con-
firming that the phenotypic differences resulted from APOL1
alteration (Figures 2C and S4A). The APOL1D-APOL3KO pheno-
type also included the surface area reduction of mitochondria
(Figure 2E), Golgi apparatus (Figure 2F), and ER tubules
(Figure S4B), suggestive of increased membrane fission.Cell Reports 30, 3821–3836, March 17, 2020 3823
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Figure 2. APOL1D Expression or APOL3KO Triggers Actomyosin Reorganization
(A) Cellular area and perimeter of the different podocyte cell lines. WT, n = 96; 1KO, n = 84; 1Dhom, n = 127; 3KO, n = 98; 1+3KO, n = 84; 2KO, n = 61.
(B) Cellular adhesion of the different podocyte cell lines on fibronectin-coated plates.WT, n = 12; 1KO, n = 8; 1Dhom, n = 12; 3KO, n = 12; 1+3KO, n = 12; 2KO, n = 10.
(C) Cellular motility and adhesion foci size of the different podocyte cell lines as determined by vinculin immunostaining. Speed panel: WT, n = 240; 1KO, n = 148;
1Dhom,n=223;3KO,n=191;1+3KO,n=86; 2KO,n=75; 1D+addb, n=99. Focal adhesionsizepanel:WT, n=970;1KO,n=1,628;1Dhom,n=2,006;3KO,n=1,706.
(D) Actin and tropomyosin immunofluorescence confocal microscopy of representative samples of the different podocyte cell lines (n = 3).
(E) Mitochondria size morphology of the different podocyte cell lines as determined by MicroP software analysis. WT, n = 24; 1KO, n = 24; 1Dhom, n = 12; 3KO,
n = 22; 1+3KO, n = 9.
(F) Golgi extent of the different podocyte cell lines as determined by Golgin97 staining. WT, n = 51; 1KO, n = 34; 1Dhom, n = 66; 3KO, n = 72; 1+3KO, n = 51.
All results are expressed as means ± SDs. All scale bars, 20 mm.Accordingly, in these podocytes, a larger fraction of the ER and
ER-linked inverted formin 2 (INF2), which recruits actomyosin on
ER for organelle fission (Chakrabarti et al., 2018; Curchoe and
Manor, 2017; Hatch et al., 2014), was associated with the non-
muscular myosin NM2A heavy-chain MYH9 (Figure S4C).
Thus, in addition to the inhibition of APOL involvement in
poly(I:C)-induced cell death, APOL1D expression or APOL3KO
induced similar podocyte actomyosin reorganization for reduced
cellular adherence, increased motility, and increased organelle
fission.
Either APOL1 C-Terminal Helix Truncation or APOL3KO
Inhibits PI(4)P Synthesis at the Golgi
Several actomyosin components, such as MYH9 and gelsolin,
share the ability of APOL1 to bind phosphoinositides (Liu3824 Cell Reports 30, 3821–3836, March 17, 2020et al., 2016; Nag et al., 2013). Therefore, we investigated
whether the effects of APOLs on actomyosin organization
may be related to their ability to bind these phospholipids.
APOL1 and APOL3 exhibited extensive co-localization with
the major Golgi phosphoinositide PI(4)P (Figure 3A). In
APOL1D and APOL3KO cells, but not in the APOL1KO and
APOL1+3KO cells, the PI(4)P content was strongly reduced
with respect to WT cells (Figures 3B and S5A), and the Golgi
exhibited the typical condensation observed following exper-
imental PI(4)P depletion (Dippold et al., 2009) (Figures 2F
and S5B). APOL1 and APOL3 appeared to exert, respectively,
negative and positive effects on PI(4)P content, since their
respective absence was associated with a slight increase or
a strong decrease in PI(4)P levels (Figures 3B, S5A, and
S5B). The overexpression of APOLs induced by poly(I:C)
A B
C
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Figure 3. APOL1 and APOL3 Control PI(4)P Synthesis
(A) Co-localization of APOL1 and APOL3 with PI(4)P. APOL1, n = 22; APOL3V5, n = 19.
(B)Relative content ofPI(4)P andGolgi-associatedPI(4)P in the different podocyte lines.NormalizedPI(4)Ppanel:WT, n = 55; 1KO, n = 21; 1Dhom, n = 61; 3KO, n = 27;
1+3KO, n = 14; WT+poly(I:C), n = 15. GMP130/PI(4)P overlap panel: WT, n = 24; 1KO, n = 22; 1Dhom, n = 29; 3KO, n = 36; 1+3KO, n = 28; WT+poly(I:C), n = 15.
(C) Relative content of PI(4,5)P2 in WT, APOL1D, and APOL3KO cells. WT, n = 17; 1Dhom, n = 15; 1KO, n = 14.
(D) Western blot analysis of total cellular extracts and PI4KB immunoprecipitates from various podocyte lines. Immunoprecipitates loading corresponds to 20- to
25-fold more cellular material than total extracts loading.
(E) PI(4)P synthesis by recombinant PI4KB (50 ng) with or without the addition of different recombinant proteins, expressed as percentage of activity without
addition. The activity without PI substrate or without PI4KB (<0.1%) was subtracted.
(F) Surface area comparison of trans-Golgi network and Golgi stacks between different podocytes lines, as determined by transmission electron microscopy
(bars, 500 nm). The yellow stars label vesicles of the trans-Golgi network. WT, n = 39; 1Dhom, n = 17.
All scale bars, 20 mm. Quantitative measurements are expressed as means ± SDs.only slightly affected PI(4)P (Figure 3B). In contrast to PI(4)P at
the Golgi, PI(4,5)P2 levels at the plasma membrane were
similar between cell lines (Figure 3C), suggesting that the
cellular phenotype was specifically related to Golgi PI(4)P.
As shown in Figure 3D, the reduction of PI(4)P was not due
to the reduced expression of PI4KB or NCS-1, a PI4KB acti-
vator (de Barry et al., 2006; Haynes et al., 2005; Mikhaylova
et al., 2009; Taverna et al., 2002; Zhao et al., 2001). Likewise,
it was not explained by the increased expression or delocal-
ization of the PI(4)P phosphatase SAC-1 (Del Bel and Brill,
2018) to the trans-Golgi (Figures 3D and S5C). Thus, it likely
resulted from PI4KB inactivation. In PI4KB immunoprecipi-tates, PI4KB activity was too low to reliably detect differences
between cell lines, possibly due to inefficient NCS-1 co-immu-
noprecipitation with PI4KB (Figure 3D). Under in vitro condi-
tions, APOL3, but not NCS-1, triggered the Ca2+-dependent
stimulation of PI4KB activity (Figure 3E). This stimulation
also occurred with APOL1 or with APOL3+NCS-1, but at a
lower level (Figure 3E). Thus, in APOL3KO and APOL1D cells,
APOL3 absence or eventual APOL3 inactivation could ac-
count for the reduction in PI4KB activity.
In line with the relation between APOL3 and PI4KB activity,
APOL3 was found to co-localize with PI4KB, together with
NCS-1 and with the PI(4)P- and myosin-binding proteinCell Reports 30, 3821–3836, March 17, 2020 3825
GOLPH3 (Dippold et al., 2009) (Figure S5D). Moreover, in
APOL1D podocytes, the co-localization of PI4KB, NCS-1,
and GOLPH3 with APOL3 was reduced (Figure S5D),
although PI4KB and NCS-1 remained closely associated
(Figure S5D).
In accordance with the role of PI(4)P in secretion, the lowering
of PI(4)P in APOL1D cells was associated with the surface area
reduction of the trans-Golgi vesicular network and collapse of
Golgi stacks (Figure 3F).
We conclude that besides the ability of APOLs to bind phos-
phoinositides, their activity is related to in vivo PI(4)P synthesis
by PI4KB at the Golgi.
APOL1 Only Indirectly Associates with Actomyosin
Components
We undertook a search for APOL1 partners that would partici-
pate in the APOL1 effects on actomyosin through themodulation
of PI(4)P synthesis. The immunoprecipitation of APOL1 from
NP-40 detergent-treated cellular extracts selectively pulled
down several actomyosin components, particularly NM2A
(heavy-chain MYH9, regulatory light-chain MYL9/12A, and
essential light-chain MYL6), together with gelsolin and tropomy-
osin, but not actin (Figure S6). However, approaches aiming at
identifying direct association with APOL1 did not reveal these
components (see below). Thus, both APOL1 association with
actomyosin components and effects on actomyosin organiza-
tion could be indirect, possibly through phosphoinositide
binding.
Alteration of the C-Terminal Helix Affects APOL1
Folding
To identify components directly interacting with APOL1, yeast
two-hybrid (Y2H) screening was performed in a podocyte
cDNA expression library (Figures S7A–S7C). This screen re-
vealed frequent interactions between N- and C-terminal
APOL1 sequences, the smallest interacting domains (SIDs) be-
ing, respectively, the 78–121 and 346–390 stretches (desig-
nated, respectively, SID1 and SID2; Figures S7C–S7E). APOL1
SID1 also interactedwith the APOL2 and APOL3C termini, which
share extensive sequence similarity with SID2 (Figures S7C–
S7E). The two SIDs exhibited a similar structure, with a hydro-
phobic cluster (HC) followed by a LZ (Figures 4A and S7E).
More stringent conditions of Y2H screening still allowed interac-
tions between SIDs and revealed that G2mutations reduced this
interaction (Figures S8A and S8B). The SID1 sequence was sub-
sequently mutated to destroy the heptad repeat hydrophobicity
in LZ1 (LZ1mut: L111Q/L115Q/L118Q). These mutations did
not inactivate APOL1, since the LZ1mut mutant displayed
conserved trypanolytic potential (Figure S8C), but they disrupted
the interaction between SIDs (Figure S8D), revealing the role of
LZs in this process.
Surface plasmon resonance (SPR) measurements confirmed
the interaction between the SID1 and SID2 peptides (Figure 4B).
Both HC and LZ sequences contributed to this interaction, since
HC1 deletion (in the LZ1p peptide), LZ2 deletion (in the HC2p
peptide), and LZ2 mutations (in the G1Cp-G2Cp peptides)
affected the interaction (Figures 4B and 4C). The LZ1p peptide
did not interact with HC2p (Figures 4B and 4C), supporting the3826 Cell Reports 30, 3821–3836, March 17, 2020hypothesis that the interaction between SID1 and SID2 is driven
by both HC1-HC2 and LZ1-LZ2 interactions.
Evidence that such interactions occur in ciswithin APOL1 was
impossible to verify experimentally due to the aggregation of
recombinant APOL1, which prevented analysis by either intra-
molecular fluorescence resonance energy transfer or double
electron-electron resonance. However, during electrophoresis
with SDS, APOL1D exhibited faster migration than expected
from its size (34.4 kDa), a discrepancy that was not seen for
WT APOL1 (Figure 4D). Since such a mobility shift in SDS results
from increased hydrophobicity (Rath et al., 2009), LZ2 deletion
appeared to increase APOL1 hydrophobicity. Accordingly, the
removal of HC2 from APOL1D (in APOL1D1) restored the ex-
pected electrophoretic mobility (Figure 4D). The increased expo-
sure of HC2 following LZ2 deletion suggested that LZ2 favors
HC2 cis-interaction with HC1 in SID1. In the case of the G1
and G2 variants, no electrophoretic mobility shift could be de-
tected (Figure 4D), but staining of these proteins with Nile red
also revealed increased hydrophobicity with respect to WT
APOL1 (Figure 4E).
These observations suggested that WT APOL1 is folded
through cis-interaction between SID1 and SID2 and that deletion
or mutation of LZ2 disrupts APOL1 folding, increasing the expo-
sure of HCs (Figure 4F).
Alteration of the C-Terminal Helix Increases APOL1
Interaction with APOL3
Y2H screening indicated that the N-terminal region of APOL1
can interact at low frequency with the C-terminal region of
APOL3 (Figure S7D). SPR measurements confirmed that
APOL1 SID1p interacts with the APOL3 sequence homologous
to SID2 (A3Cp). This interaction exhibited lower affinity than
that between APOL1 SIDs and was strongly dependent on
HC1 (Figures 4B and 4C).
Using biolayer interferometry (BLI) measurements, only weak
binding was observed between WT APOL1 and APOL3 (Fig-
ure 5A), but the binding increased when LZ2 was deleted
(APOL1D) or distorted (G1 and G2), or when LZ1 was disrupted
(LZ1mut) (Figure 5A). Thus, reducing the probability of interac-
tions between SID1 and SID2 led to the increased binding of
APOL1 to APOL3 (models in Figures 4F and 4G). This binding
did not require Ca2+ (Figure 5A).
Gene co-expression using the pDUET system in Escherichia
coli confirmed that APOL1 and APOL1 variants can interact
with APOL3 (Figure 5B, top panel). As a control, neither WT
APOL1 nor APOL1D interacted with tropomyosin.
Finally, in support of APOL1-APOL3 interaction in vivo, APOL1
was detected in FLAG immunoprecipitates from WT-APOL3-
FLAG cells (Figure 5C).
We conclude that APOL1 can bind to APOL3 in a mechanism
enhanced by the alteration of either LZ2 or LZ1.
Intracellular APOL1 Topology Is Compatible with
APOL1-APOL3 Interaction
Since APOL1 and APOL3 are supposed to be on opposite faces
of intracellular membranes due to the presence of the signal
peptide in APOL1 only, the biological relevance of the interac-
tion between these proteins was questionable. Therefore, we
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Figure 4. SID1 Interactions with SID2 Inhibit HC Exposure in APOL1
(A) Sequences of the synthetic peptides used for SPR measurements (SID1p and LZ1p = APOL1 K73-K125 and L88-K125; SID2p, G1Cp, G2Cp = APOL1 G332-
L392 from WT or variant sequences; A3Cp = APOL3 G265-L325). Violet and pink colors highlight residues defining the hydrophobic clusters (HC, violet) and
leucine zippers (LZ, pink). Yellow and green colors, respectively, indicate the N-term tag used for coupling the peptides to the SPR chip and residues specific to
G1 and G2 variants. In A3Cp, residues evoking the APOL1 G1 or G2 variants are shown in blue.
(B) SPR-determined binding parameters for the interactions of the SID1p and LZ1p peptides to various immobilized peptides.
(C) SPR sensorgrams of interactions between SID peptides.
(D) Electrophoretic mobility shift of APOL1D. A1, D and D1 = APOL1 60–398, 60–353, and 60–342, respectively (expected sizes: 41.3, 34.4, and 32.2 kDa). The
sequence of the APOL1D band excised from the SDS-PAGE gel was determined bymass spectrometry to check its integrity (peptide coverage in yellow; oxidized
methionines in green). The HC2 sequence is underlined, and the C terminus of APOL1D1 is denoted by an arrow.
(E) Nile red staining of recombinant APOL1, G1, or G2 (1 mM each). Fluorescence emitted by Nile red (0.01 mM) was measured at 630 nm (fluorescence of APOL1
was set to 1). Error bars, SDs; n = 9.
(F) Model for the interactions between SIDs in APOL1. LZ2 with a star, mutant leucine zipper, exhibiting reduced interaction affinity with LZ1. K+ refers to channel
activity (parentheses denote inactivation).
(G) Model for the interactions between APOL3 and NCS-1 (top) or APOL1D+NCS-1 (bottom). The APOL3 sequences homologous to APOL1 HCs and LZs are
indicated in italics. K+ refers to channel activity (parentheses denote inactivation).investigated the topology of APOL1 by immunogold electron mi-
croscopy. Labeling with anti-APOL1 antibody revealed clusters
of gold particles in the cytosol of WT cells (Figure S9A), and
such particles were never seen in the cytosol of APOL1KO cells
(data not shown). Part of this labeling was localized close to the
mitochondrion (Figure S9A). No ER or Golgi membrane-associ-
ated APOL1 labeling was detected, suggesting that epitopes
of membrane-inserted APOL1 are not accessible to the antibody
under the immunogold conditions, which exclude treatment with
detergents.
The presence of cytosolic APOL1 could be related to differential
processing between intracellular and secreted APOL1, since theapparent size of APOL1, as deduced from electrophoresis with
SDS, differed between podocyte extracts and human serum (Fig-
ure S9B). The expression of APOL1 isoforms unable to be
secreted (isoforms 2 and 3, respectively; NCBI: NP_663318.1
and NP_001130013.1) could account for this observation, since
transcripts for these isoformswere detected in podocytes (Cheat-
ham et al., 2018). In particular, transcripts for isoform 3 repre-
sented 5% of total APOL1 transcripts (Figure S9C). A possible
cleavage in isoform 3, resulting in an improbable signal peptide
unlikely to allow membrane translocation (12 hydrophobic resi-
dues instead of 17 inWT APOL1), would confer the size observed
for intracellular APOL1 (Figures S9D and S9E). In support of thisCell Reports 30, 3821–3836, March 17, 2020 3827
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Figure 5. APOL1 C-Terminal Variation Influences APOL3 Binding to APOL1 and NCS-1
(A) BLI measurements of interaction between bound APOL3 and recombinant WT APOL1 or APOL1 variants, either in SID1 (LZ1mut) or SID2 (APOL1D, G1, G2)
(n = 3).
(B) Interactions between APOLs and APOL3 (top panel) or NCS-1 (bottom panel), as measured in the E. coli pDUET co-expression system. Nickel binding of
S-tagged proteins reflects their association with His-tagged partners (highlighted within red frames). A1, D, and D1 = APOL1 60-398, 60-353, and 60-342,
respectively; A3 = APOL3; 3N = APOL3+1% NP-40 instead of 1% CHAPS; M3 = APOL3 HC2-like mutant HCmut. These data are representative of at least 5
independent experiments.
(C) Western blot analysis of APOL1, TriFLAG-tagged APOL3, and NCS-1 immunoprecipitates from podocytes. All of the extracts were treated with 1% CHAPS.
(D) BLI measurements of interactions between bound NCS-1 and APOL3 under various calcium concentrations (n = 3).
(E) BLI measurements of interactions between bound NCS-1 and various recombinant APOLs, either WT or variant in SID1 (LZ1mut) or in SID2 (APOL1D, G1, G2),
performed in the presence of 50 mM CaCl2 (n = 3).
(F) BLI measurements of interactions between bound NCS-1 and APOL3, in the presence or absence of either 1% NP-40 or 1% CHAPS (n = 3).
(G) BLI measurements of interactions between bound NCS-1 and APOL3 or PI4KB, added sequentially as indicated (n = 3).
(H) BLI measurements of interactions between bound NCS-1 and APOL3, either alone or mixed with different molar ratios of APOL1 (left panel) or APOL1D (right
panel) (n = 3).hypothesis, APOL1 isoform 3 lacks the exon 4 sequence, which is
unlikely to be present in intracellular APOL1 since this sequence is
strongly cytotoxic (Khatua et al., 2015).
The protein fractionation data presented in Figure 1E sug-
gested that most intracellular APOL1 behaves like the trans-
membrane protein calnexin. Since the APOL1D intracellular
distribution pattern mimicked that of APOL1 (Figure 1E), APOL1-
D should be inserted into membranes like APOL1.
In conclusion, intracellular APOL1 is processed differently
from the secreted fraction and could be encoded by isoform 33828 Cell Reports 30, 3821–3836, March 17, 2020transcripts. This APOL1 fraction could share the cytoplasmic
localization of APOL3.
APOL3, but Not APOL1, Interactswith NCS-1, Promoting
Association of NCS-1 with PI4KB
Y2H screening only detected infrequent interactions between
the N- and C-terminal regions of APOL3 (Figure S10A), contrast-
ing strikingly with the high frequency of such interactions in the
case of APOL1. Thus, in the case of APOL3, internal SID1-
SID2-like interactions are improbable. Accordingly, the APOL3
sequence homologous to APOL1 LZ1 exhibited a much lower
coiled-coiling potential than that of APOL1 (Figure S10B). Y2H
screening with full APOL3, inactivated by site-directed mutagen-
esis of the transmembrane hairpin loop to avoid toxicity (APOL3
null: L137Q/A138Q/P139S/G143S) (Fontaine et al., 2017), identi-
fied NCS-1 as a major interacting partner (Figure S10C). Such an
interaction with NCS-1 was not observed for inactivated APOL1
or APOL1D (null mutants: P198S/G202S/G203S) (Figures S8C
and S8E).
Gene co-expression in the E. coli pDUET system confirmed
both APOL3-NCS-1 interaction and the absence of APOL1-
NCS-1 interaction (Figure 5B, bottom panel). APOL3 interaction
with NCS-1 required the HC2-like sequence, as it was lost
following HC mutagenesis (HCmut: I276Q/F277A/L280Q/
V283Q/Y287Q) (Figure 5B, lane M3), which still conserved trypa-
nolytic activity (Figure S8C). Binding of the APOL3 HC2-like
sequence to NCS-1 was in keeping with the strong hydrophobic
nature of peptide interactions with NCS-1 (Pandalaneni et al.,
2015), which also explains the loss of APOL3-NCS-1 interaction
occurring with the non-ionic detergent NP-40, but not with the
ionic detergent CHAPS (Figure 5B, bottom panel, lane 3N). In
accordance with these observations, NCS-1 and APOL3FLAG
were found to be present in, respectively, FLAG and NCS-1 im-
munoprecipitates from CHAPS-treated extracts of APOL3FLAG
podocytes (Figure 5C).
More detailed measurements of protein interactions by BLI re-
vealed that the interaction of APOL3 with NCS-1 required Ca2+,
within concentrations found at the cytoplasmic periphery of ER
membranes (1–100 mM) (R€udiger et al., 2010; Figure 5D). Interac-
tion of APOL3 with NCS-1 contrasted strikingly with the lack of
APOL1-NCS-1 interaction (Figure 5E). The hydrophobic nature
of the APOL3-NCS-1 interaction was confirmed bymutagenesis.
Mutations altering either the APOL3 HC2-like sequence (HCmut)
or the hydrophobic crevice surface of NCS-1 such as L89K or
F85K (Pandalaneni et al., 2015) reduced the interaction (Figures
S11A and S11B). Moreover, as expected from observations in
E. coli (Figure 5B), the APOL3-NCS-1 interaction was abolished
in NP-40, but not in CHAPS (Figure 5F). The interaction between
APOL3 and NCS-1 exhibited high affinity (Kd = 36.5 ± 2.6 nM;
Figure S11C), comparable to that measured for interaction be-
tween the yeast PI4KB and NCS-1 homologs Pik1 and Frq1,
which also involves hydrophobic bonds (Kd 100 nM) (Huttner
et al., 2003; Strahl et al., 2003, 2007). The APOL3-NCS-1 interac-
tion occurred irrespective of NCS-1 N-myristoylation (Figures
5G, S11D, and S11E), contrasting with the requirement of N-myr-
istoylation for the interaction of NCS-1 with PI4KB (Zhao et al.,
2001). Remarkably, APOL3 increased the interaction of NCS-1,
even non-myristoylated, with PI4KB (Figures 5G and S11E).
In summary, APOL3, but not APOL1, exhibited high affinity
and Ca2+-dependent interaction with NCS-1. This interaction
occurred through hydrophobic contacts involving the APOL3
HC2-like sequence (Figure 4G) and promoted the association
of NCS-1 with PI4KB.
APOL1 and APOL1 C-Terminal Variants Can Affect the
Formation of the APOL3-NCS-1 Complex
We evaluated the effect of the interaction of APOL1 with APOL3
on the APOL3 association with NCS-1. When present in excess,APOL1 reduced the interaction between APOL3 and NCS-1, but
in contrast, APOL1D contributed to the increase in the signal of
NCS-1 binding (Figure 5H, left and right panels, respectively).
Since APOL1D did not bind to NCS-1 (Figure 5E), the latter
observation indicated that a tripartite APOL1D-APOL3-NCS-1
complex was formed (Figure 4G). However, neither APOL1 nor
APOL1D were able to bind to the preformed APOL3-NCS-1
complex (Figure S11F). The G2 and G1 variants behaved like
APOL1 and not like APOL1D, since they reduced the interaction
between APOL3 and NCS-1 (Figure S11G).
We conclude that APOL1 and the G1 and G2 variants can
hinder the association of APOL3 with NCS-1, whereas APOL1D
appeared to strengthen this association. Thus, the binding of
APOL1 to APOL3 clearly interfered with APOL3-NCS-1 interac-
tions, and this occurred in different ways, depending on the
presence or absence of LZ2.
In Keeping with Its Association with NCS-1, APOL3
Exhibits K+ Channel Activity
NCS-1 is known to interact with cation channels (Guo et al.,
2002; Schlecker et al., 2006). Given its interaction with NCS-1
and its trypanolytic potential (Fontaine et al., 2017), APOL3
was expected to be an ion channel. In planar lipid bilayers at
neutral pH, APOL3 generated voltage-independent K+-selective
channels (Figure 6A). APOL3 differed fromAPOL1 since the latter
required acidic pH for membrane insertion and exhibited
voltage-dependent channel activity (Fontaine et al., 2017;
Pe´rez-Morga et al., 2005; Thomson and Finkelstein, 2015).
APOL3 channel activity was unaffected by the presence of
PI(4)P (data not shown).
Given the topology of these channels in intracellular mem-
branes, both APOL3 and APOL1 could similarly drive cyto-
plasmic K+ influx into the ER and/or Golgi (Figure 6B).
APOL1 and APOL1D Inhibit In Vitro Channel Activity of
the APOL3-NCS-1 Complex
At neutral pH, APOL1 or APOL1D cannot insert into membranes,
and even at low pH, APOL1D is inactive (Thomson and Finkel-
stein, 2015). This allowed us to study the effects of APOL1 or
APOL1D on APOL3 activity. NCS-1, APOL1, or APOL1D did
not inhibit APOL3 channel activity (Figure 6C). However, if
NCS-1 was added after APOL1 or APOL1D pre-incubation with
APOL3, no longer could channel activity be recorded, provided
Ca2+ was present (Figure 6C). Thus, Ca2+-independent APOL1
or APOL1D interaction with APOL3 appeared to inhibit the
channel activity of the Ca2+-dependent APOL3-NCS-1 complex
(Figure 4G).
APOL1 and APOL3 Influence Intracellular Ca2+ Levels
APOL1 and APOL3 K+ channel activities could serve as the ion
counter-current for Ca2+ efflux by the ER-linked and NCS-1-acti-
vated inositol 1,4,5-trisphosphate receptor (IP3R) (Schlecker
et al., 2006), or as the factors increasing Ca2+ uptake as observed
with other low conductanceK+ channels (Kuumet al., 2012, 2015).
Therefore, we investigated the effect of APOL3 channel activity on
Ca2+ release or uptake. IP3R-mediated Ca2+ release provoked by
the extracellular agonist ATP occurred in all cell lines, with overall
similar characteristics (Figure 6D). However, the Golgi Ca2+Cell Reports 30, 3821–3836, March 17, 2020 3829
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Figure 6. APOL3 Exhibits K+ Channel Activity Influencing Intracellular Ca2+ Levels
(A) APOL3 channel activity in planar soy lipid membranes (n = 5).
(B) Model of APOL-mediated ion currents in the podocyte ER and Golgi membranes.
(C) Effects of APOL1 or APOL1D on APOL3 channel activity. APOL3, APOL1, and NCS-1 were added at 56, 59, and 109 pmol/mL (n values indicated in the table).
(D) Quantification of the peak of cytosolic Ca2+ increases in response to different ATP concentrations (n = 5). The values were normalized to the signal obtained
using 100 mM ATP.
(E) Intracellular Ca2+ store contents. In the top panels, each curve is representative of one single experiment (calculated from three technical replicates). In the
lower panels, data were quantified by calculating the area under the curve (AUC) normalized versus the WT cell line (black line). In the dot plots, each cell line is
represented with a different color and each independent experiment is represented with a different symbol (left panel, n = 9; center and right panels, n = 7). Data
belonging to the same experiment (e.g., 96-well plate) are indicated with the same symbol.content was significantly reduced in APOL1D and APOL1+3KO
cells, and the ER Ca2+ content was increased in APOL3KO cells
(Figures 6D and 6E). In the Golgi, APOL1 and APOL3 could exert
redundant Ca2+-controlling activity so that either the loss of both
APOLs in APOL1+3KO cells or the inactivation of both APOLs in
APOL1D cells would be required to reduce the Ca2+ level. In the
ER, the absence of APOL3 could promote APOL1-mediated
Ca2+ uptake.
We conclude that both APOL1 and APOL3 contribute to
increasing the level of Ca2+ in intracellular stores.
Urinary and Glomerular G1 or G2 Podocytes Exhibit an
APOL1D or APOL3KO-like Phenotype
To relate our findings with KD, podocytes were obtained from
the urine of a G2/G2 individual suffering from CKD stage 43830 Cell Reports 30, 3821–3836, March 17, 2020post-perinatal asphyxia (Figures S12A–S12D) and from the
urine of G1/G2 patients suffering from focal segmental
glomerulosclerosis (FSGS) or HIV-associated nephropathy
(HIVAN) (Okamoto et al., 2018), and we compared their anal-
ysis with that of WT (G0/G0) controls. Urinary podocytes
from the G2/G2 individual exhibited a mild APOL1D pheno-
type, regarding their surface area, motility, PI(4)P content,
and Golgi morphology (Figures 7A–7D). Significantly, reduc-
tion of PI(4)P content coupled to Golgi condensation was
also observed in podocyte cell lines established from the urine
of the FSGS and HIVAN G1/G2 patients (Figures 7E and 7F).
Furthermore, in kidney biopsies from G1/G1 and G2/G2 pa-
tients (Gaillard et al., 2018), the mean PI(4)P level of glomeruli
was clearly reduced with respect to the levels of WT individ-
uals (Figure 7G).
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Figure 7. Urine and Glomerular G1 and G2 Podocytes Exhibit an APOL1D or APOL3KO-like Phenotype
(A) Surface and perimeter measurements of urine APOL1 WT (Ur Ctrl) and G2/G2 podocytes from an individual with stage 4 CKD. Ur Ctrl, n = 132; G2, n = 120.
(B) Cellular motility of podocytes described in (A). Ur Ctrl, n = 192; G2, n = 186.
(C) PI(4)P level of podocytes described in (A). Ur Ctrl, n = 77; G2, n = 71.
(D) Size of Golgi stacks in podocytes described in (A), as determined by transmission electron microscopy (TEM) analysis. Ur Ctrl, n = 49; G2, n = 50.
(E) PI(4)P level in urine APOL1 G0/G0 and G1/G2 podocytes from FSGS or HIVAN disease patients. G0, n = 31; FSGS, n = 30; HIVAN, n = 41.
(F) Golgi extent in urine APOL1G0/G0 andG1/G2 podocytes from FSGS or HIVAN disease patients, as determined byGolgin97 staining. G0, n = 32; FSGS, n = 32;
HIVAN, n = 34.
(G) PI(4)P level in glomeruli from biopsies from G0/G0, G1/G1, or G2/G2 transplanted kidneys. Glomeruli (G) and control regions (Ctrl) were analyzed for
immunostaining with anti-PI(4)P antibodies. In the graph, the different-colored dots identify different donors. G0, n = 37; G1, n = 94; G2, n = 19.
All of the quantitative results are expressed as means ± SDs.We conclude that the disease phenotype linked to the expres-
sion of C-terminal APOL1 variants is related to the reduction of
PI(4)P at the Golgi.
DISCUSSION
We report that in kidney podocytes, either alteration of the C-ter-
minal helix (LZ2) of APOL1 or deletion of APOL3 trigger reduction
of PI(4)P synthesis at the Golgi, concomitant with actomyosin
reorganization increasing cellular motility and organelle fission.
As observed with actomyosin mutations (Brown et al., 2010; Ka-
plan et al., 2000), such a reorganization is susceptible to induce
KD through podocyte dysfunction. In support of this view, in
addition to the APOL1 variants G1 and G2, an APOL3 null variant
allele was also found to exhibit significant association with KD
(Skorecki et al., 2018).We provide evidence that intracellular APOL1, which is pre-
sent in the cytosol as a protein processed differently from
secreted APOL1, can interact with APOL3 and that this interac-
tion is increased by LZ2 deletion or mutations. We propose that
in WT APOL1, cis-interaction between N- and C-terminal helices
(LZ1 and LZ2) limits trans-interaction with APOL3, and that LZ2
alteration relieves this limitation (Figures 4F and 4G). Since LZ2
deletion in APOL1D cells induced a phenotype strikingly similar
to that of APOL3KO, the APOL1-APOL3 interaction resulting
from LZ2 deletion should inactivate APOL3. Accordingly, we
found that APOL1 inhibits APOL3 channel activity when NCS-1
is present.
We show that APOL3, but not APOL1, binds with high affinity
to NCS-1. This binding occurred with Ca2+ concentrations found
in the cytoplasm close to IP3R and NCS-1 (R€udiger et al., 2010).
In vivo, NCS-1 requires high Ca2+ levels to activate PI4KBCell Reports 30, 3821–3836, March 17, 2020 3831
(de Barry et al., 2006; Mikhaylova et al., 2009). Accordingly, our
data indicated that Ca2+-dependent APOL3 binding to NCS-1
promotes NCS-1 interaction with PI4KB. In vitro, Ca2+ is not
mandatory for PI4KB activation by N-myristoylated NCS-1
(Zhao et al., 2001), but we observed Ca2+-dependent activation
of PI4KB by APOL3. In vitro assays cannot mimic in vivo condi-
tions for PI4KB activity, which involves recruitment of the kinase
to trans-Golgi membranes. However, they revealed APOL3 as a
possible PI4KB activator besides NCS-1. Since we did not find
evidence for interaction between APOL3 and PI4KB unless
NCS-1 was added, it is possible that despite its ability to directly
activate PI4KB in vitro, in vivo APOL3 should interact with NCS-1
to activate PI4KB, explaining the Ca2+ dependence of this
activation.
In keeping with their contrasting capability to interact with
NCS-1, APOL1 and APOL3 appeared to differentially affect
PI4KB in vivo, leading to, respectively, higher or lower PI(4)P
levels when absent. In vivo, PI4KB activity is controlled by
competition between inhibitory calneurons at low Ca2+ levels
and stimulatory NCS-1 at high Ca2+ levels (Mikhaylova et al.,
2009). Based on these observations, we propose a model for
APOL involvement in PI4KB control (Figure S13A). APOL3
would activate PI4KB at high Ca2+ levels, dissociating the
calneuron-PI4KB interaction because APOL3 promotes the as-
sociation of NCS-1 with PI4KB. Therefore, in the absence of
APOL3, such as in APOL3KO cells, PI4KB activity would be
reduced even at high Ca2+ levels following conserved interac-
tion with calneurons. In APOL1D cells, increased APOL1 bind-
ing to APOL3 would interfere with the interaction of APOL3 and
NCS-1, thus inactivating APOL3. In APOL1KO cells, the slight
increase in the PI(4)P level could result from the loss of
the ability of APOL1 to hinder APOL3-NCS-1 interaction. In
APOL1+3KO cells, paradoxically, PI4KB appeared to be active
despite the absence of APOL3. Such activity could result from
the interaction of PI4KB and N-myristoylated NCS-1 (Zhao
et al., 2001). Since the only difference between APOL3KO
and APOL1+3KO cells is the absence of APOL1 in the latter
case, it appears that in the absence of APOL3, APOL1 inhibits
PI4KB activation by NCS-1. Since APOL3KO cells but not
APOL1+3KO cells exhibited increased Ca2+ uptake in luminal
ER stores, the absence of APOL3 alone may favor calneuron
activity due to increased cytosolic Ca2+ depletion by APOL1.
Moreover, calneuron-1 is also known to participate in Ca2+
storage in the ER (Kobuke et al., 2018).
We show that APOL1 indirectly associates with actomyosin
components, particularly NM2A, gelsolin, and tropomyosin,
and that editing of APOLs triggers actomyosin reorganization,
while also affecting both organelle fission and Golgi structure.
Organelle fission and Golgi-derived secretion involve annular
membrane contraction by actin, which is dependent on non-
muscle myosin 2A (NM2A) activity (Chakrabarti et al., 2018;
Curchoe and Manor, 2017; Hatch et al., 2014, 2016; Miserey-
Lenkei et al., 2017). The inhibitory effect of APOLs on organelle
fission, also observed with APOL1 in trypanosomes (Vanwalle-
ghem et al., 2015), could involve their strong binding to cardioli-
pin and phosphatidic acid, known to be key components
recruiting the fission machinery to the mitochondrion and Golgi
(Frohman, 2015; Kameoka et al., 2018; Pagliuso et al., 2016).3832 Cell Reports 30, 3821–3836, March 17, 2020In addition, the effects of APOLs on PI(4)P levels are clearly ex-
pected to affect secretion, cellular traffic, and autophagy (Fig-
ure S13B), explaining the podocyte vesicular trafficking prob-
lems that are observed following the expression of APOL1
C-terminal variants either in vitro (Beckerman and Susztak,
2018) or in mice (Beckerman et al., 2017).
We propose that the G1 or G2 variants cause an APOL1D-like
phenotype because reduction of PI(4)P synthesis was observed
in both urine podocytes and kidney glomeruli from G1 or G2 in-
dividuals. The G1 or G2 variants could result from a compromise
between the requirement for the disruption of LZ2 interaction
with the N-terminal LZ of SRA to resist T. b. rhodesiense and
the necessity of preserving LZ2 interaction with APOL1 LZ1 to
avoid actomyosin reorganization by unfolded APOL1. Maintain-
ing a level of LZ2-LZ1 interaction may also be necessary for
APOL1 channel activity, because in contrast to what occurs
with the G1 or G2 mutations, either C-terminal truncation or
SRA binding to this region completely inhibit this activity (Lecor-
dier et al., 2009; Thomson and Finkelstein, 2015). While still al-
lowing some LZ2 interaction with LZ1, the G1 or G2 mutations
could destabilize the LZ2 structure enough to increase APOL1
binding to APOL3, preventing APOL3-mediated activation of
PI4KB, and therefore progressively inducing podocyte dysfunc-
tions responsible for CKD.STAR+METHODS
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Deposited Data
Proteins identified by mass spectrometry in podocyte
extracts immunoprecipitated with anti-APOL1 antibody
This paper; and
PRIDE archive
Data available via ProteomeXchange with
identifier PXD016851
Experimental Models: Cell Lines
WT TriFlag This study N/A
WT 3V5 This study N/A
1 Dhom 3V5 This study N/A
1KO 3V5 This study N/A
WT APOL1 addback This study N/A
Dhom This study N/A
Dhet This study N/A
2KO This study N/A
3KO This study N/A
1+3KO This study N/A
Oligonucleotides
CCGGCCAGGCAAAAAAGAAAAAGG This study T2A for
AGTGCTATCCACTGGGCCAGGATTCTCCTCG This study T2A rev
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GCTGATCAGCGAGCTCTAGTTAGCCCTGGAACAGGT
GGTGGCGGG
This study E2-Crimson rev
CACCGCACTGGTCTGGGGTCAGT This study APOL3 sgRNA for
AAACACTGACCCCAGACCAGTGC This study APOL3 sgRNA rev
TTGCATGCCTGCAGGTCGACTATGAGGCAGATG
CTCTCTACG
This study APOL3 ORF for
ACTTCCCAGCGGGCCCTGGAACAATACTTCCAG
ATCACTGCCGTGGGTATGGCATGGATTCAGA
This study APOL3 ORF rev
CTGTACAAGTAGCCCCAGACCAGTGCAGCC This study APOL3 UTR for
AATTCGAGCTCGGTACCCGGGTTACACACAGGG
CACTCAGC
This study APOL3 UTR rev
CCAGGGCCCGCTGGGAAGTGGCAAACCGATTCCG
AACCCGCTTCTTGGTCTAGACAGCACCGGTGGCAG
TGGAGAGGGCAGA
This study V5-GFP for
GTCTGGGGCTACTTGTACAGCTCGTCCATGCC This study V5-GFP rev
CCAGGGCCCGCTGGGAAGTGATTATAAGGATCATG
ATGGTGACTACAAAGACCATGATATCGATTACAAAG
ATGATGACAAGGGTGGCAGTGGAGAGGGCAGA
This study TriFlag-GFP for
GTCTGGGGCTACTTGTACAGCTCGTCCATGCC This study TriFlag-GFP rev
CCCTCGTAAAGAATTCATGTCAGAGGAAGCTGGA
GCGAGG
This study APOL1 TetOne for
GCAGAGATCTGGATCCTCACAGTTCTTGGTCCGC
CTGCAG
This study APOL1 TetOne rev
GTCACTGAGCCAATCTCAGC This study APOL1 exon 7 Fw
CATATCTCTCCTGGTGGCTG This study APOL1 exon 7 Rv
CCAGCTTTGCAATCATGAGATTC N/A APOL1 Ex2-Forward
TTCCTCTGCCCTCACTCC N/A APOL1 Ex4 Reverse
ATGGAGGGAGCTGCTTTG N/A APOL1 Ex3-Forward
TGCATCTGGGTGCAACAAA N/A APOL1 Ex 3-5 Forward
GATACTGCTCTCTGGGTCCAT N/A APOL1 Ex5-Reverse
Recombinant DNA
U6gRNA-Cas9-2A-GFP (TGTGCTGCTGGTCTTTA
TCGTGG sgRNA)
Sigma-Aldrich CRISPR APOL2
U6gRNA-Cas9-2A-GFP (TAGAACATATGCAGCTA
TTGAGG sgRNA)
Sigma-Aldrich CRISPR APOL3 exon 5
U6gRNA-Cas9-2A-GFP (AACCAGCATTGACCGA
TTGAAGG sgRNA)
Sigma-Aldrich CRISPR APOL3 exon 5
U6gRNA-Cas9-2A-GFP (AAGTAAGCCCCTCGGT
GACTGGG sgRNA)
Sigma-Aldrich CRISPR APOL1 exon 3
U6gRNA-Cas9-2A-GFP (AGTGCTTTGATTCGTAC
ACGAGG sgRNA)
Sigma-Aldrich CRISPR APOL1 exon 5
pGEM-T Easy vector Promega A137A
pSpCas9(BB)-2A-E2Crimson This study N/A
pSpCas9(BB)-2A-GFP Ran et al., 2013 Addgene plasmid # 48138
pApoL3-HRV-V5-2A-GFP This study N/A
pApoL3-HRV-TriFlag-2A-GFP This study N/A
pCDF-Duet1 Novagen N/A
Software and Algorithms
Trimmomatic v035 Bolger et al., 2014 http://www.usadellab.org/cms/?page=
trimmomatic
BWA mem v0.7.15 Li, 2013 https://github.com/lh3/bwa
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GATK v3.6-0 Van der Auwera et al.,
2013
https://github.com/broadinstitute/gatk/
SnpEFF 4.2 Cingolani et al., 2012 http://snpeff.sourceforge.net/
Picard v2.6.0 Broad Institute https://github.com/broadinstitute/picard
Samtools 1.3.1 https://github.com/samtools/samtools
ImageJ https://imagej.nih.gov/ij/
MTrackJ ImageJ plugins Meijering et al., 2012 https://imagescience.org/meijering/
software/mtrackj/
MicroP Peng et al., 2011 http://bmi.ym.edu.tw/jypeng/
MiNA Valente et al., 2017 https://github.com/StuartLab/MiNA
iTEM software Olympus GMBH N/A
JACoP plugins https://imagej.nih.gov/ij/plugins/
track/jacop.html
BIAevaluation 4.1.1. GE Lifesciences N/A
Octet Data Acquisition V10.0 ForteBio/ Molecular
Devices
N/A
Octet Data Analysis V10.0 ForteBio/ Molecular
Devices
N/A
MaxChelator Ca-EGTA Calculator v1.3 Schoenmakers et al.,
1992
https://somapp.ucdmc.ucdavis.edu/
pharmacology/bers/maxchelator/index.html
Graph-pad Prism 8 Graphpad prism https://www.graphpad.com/scientific-
software/prism/
Softmax Pro 5.4.4 Molecular devices Molecular devices
Other
DMEM-HAM’s F-12 Lonza BE04-687F/U1
Eight wells Falcon culture chamber Falcon 54118
Human fibronectin-coated 96-well Microplate R&D Systems CWP001
IbiTreat 8 well microslides Ibidi 80826
Formvar-carbon-coated copper grids Agar Scientific AGS162-3
SDS–polyacrylamide pre-cast gels Biorad 456-1033
glass beads Lysing Matrix B MP Biomedicals SKU 116911050
Biacore CM5 GE Lifesciences 29149604
Biosensor / Streptavidin (SA) Pack ForteBio/ Molecular
Devices
Ca#18-5020
Biacore Thiol Coupling Kit GE Lifesciences BR100557
EZ-Link NHS-PEG4-Biotin Thermo Scientific Ca# A39259LEAD CONTACT AND MATERIALS AVAILABILITY
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Immortalized podocytes
The conditionally immortalized human podocyte cell line described in Saleem et al. (2002) was obtained from Dr. M.A. Saleem (Uni-
versity of Bristol, UK).Cell Reports 30, 3821–3836.e1–e13, March 17, 2020 e5
Urinary G0 and G2 podocytes
Human G0 and G2 podocytes exfoliated into urine were immortalized, sub-cloned and cultivated as described below (Figure S12).
This study was approved by Ethical Research Committee of the University Hospital/KU Leuven (S61246). The participants were re-
cruited from the African community living in Belgium after signing of the informed consent form. Samples were de-identified. Neither
sex nor age is known.
Additional urinary podocytes
Control G0/G0, FSGSG1/G2 andHIVANG1/G2 urinary podocytes described in Okamoto et al. (2018) were obtained fromDr. J. Kopp
(NIH, USA).
Renal biopsies
G0/G0, G1/G1 and G2/G2 human kidney biopsy tissues were obtained from a cohort of living kidney donors of African origin,
described in Gaillard et al. (2018). All biopsies were performed as rejection screening three months post-transplantation as part of
routine work-up. All patients gave informed and signed consent. Samples were de-identified. Neither sex nor age is known.
METHOD DETAILS
Cultivation of immortalized podocytes
Cultivation of these cells was performed essentially as described (Saleem et al., 2002). Briefly, cells were grown to confluence at
33C, at which point they were trypsinized and reseeded in fresh flasks at a dilution of between 1:3 and 1:5. Before switching to
37C, cells were grown to 70 to 80% confluence. At both temperatures, cells were fed with fresh medium 3 times per week. Podo-
cytes were used after 7 to 14 days of differentiation.
Generation of APOL-edited podocytes
CRISPR-Cas9 and green fluorescent protein (GFP) fusion protein expression vectors U6gRNA-Cas9-2A-GFP guide were purchased
from Sigma-Aldrich. These vectors allow the co-expression of GFP and Cas9 from the same mRNA via a 2A peptide linkage, which
enables tracking of transfection efficiency. The RNA guide sequences are listed in Table S1A. Plasmids were transfected into immor-
talized podocytes using Cell Line Nucleofector Kit V (Lonza, Bale, Switzerland) and program T-020 (2 mg plasmid per 2 3 106 po-
docytes) with Nucleofector II apparatus (Lonza) following manufacturer’s instructions. The GFP positive cells were sorted using a
FACSAria III cell sorter (BD Biosciences, Franklin Lakes, USA) and seeded at one cell per 3 wells in 96 well-plates. The clones
were screened by western blot analysis for the lack of targeted APOL expression. The genomic DNA of the selected clones was
extracted using the Quick-DNA Plus kit (Zymo Research, Irvine, USA) following manufacturer’s instructions. The genomic region
targeted by the CRISPR/Cas9 procedure was amplified by PCR and cloned into pGEMTeasy vector (Promega). Ten clones were
sequenced and the genome of podocyte cell lines chosen to pursue the study was fully sequenced. The sequencing results are sum-
marized in Tables S1B–S1E.
In situ C-terminal tagged versions of APOL3
All the anti-APOL3 antibodies that were tested, either raised in our laboratory or commercially available, exhibited non-specific reaction
(see Figure 1B). Therefore, we generated podocyte cell lines which express the V5, TriFlag or GFP tags in fusion with APOL3. The
CRISPR-Cas9 and E2 Crimson fluorescent protein expression vector pSpCas9(BB)-2A-E2Crimson was generated as follow. The
T2A fragment was PCR-amplified from pSpCas9(BB)-2A-GFP vector using the 50- CCGGCCAGGCAAAAAAGAAAAAGG 30 and 50-
AGTGCTATCCACTGGGCCAGGATTCTCCTCG – 30 primers. The E2-Crimson fragment was PCR-amplified using the 50- TGGCCCAG
TGGATAGCACTGAGAACGTCAT30 and 50- GCTGATCAGCGAGCTCTAGTTAGCCCTGGAACAGGTGGTGGCGGG30 primers. The
T2A and E2-Crimson fragments were cloned into EcoRI digested pSpCas9(BB)-2A-GFP vector (Ran et al., 2013) using NEBuilder HiFi
DNA Assembly Master Mix (New England Biolabs, Ipswich, USA) following manufacturer’s instructions to generate pSpCas9(BB)-2A-
E2Crimson. The CRISPR-Cas9 guide RNA sequence targeting APOL3 was generated by cloning the annealed 50- CACCGCACT
GGTCTGGGGTCAGT 30 and 50- AAACACTGACCCCAGACCAGTGC 30 primers into the BbsI restricted pSpCas9(BB)-2A-
E2Crimson vector.
The C-terminal APOL3 tagging constructs pApoL3-HRV-V5-2A-GFP and pApoL3-HRV-TriFlag-2A-GFP were generated as follow.
The APOL3 ORF and APOL3 UTR fragments were PCR-amplified from podocyte gDNA using respectively the 50- TTGCATGCCTGC
AGGTCGACTATGAGGCAGATGCTCTCTACG 30 and 50- ACTTCCCAGCGGGCCCTGGAACAATACTTCCAGATCACTGCCGTGG
GTATGGCATGGATTCAGA30 primers, and the 50- CTGTACAAGTAGCCCCAGACCAGTGCAGCC 30 and 50- AATTCGAGCTCGG
TACCCGGGTTACACACAGGGCACTCAGC 30 primers. The V5-GFP and TriFlag-GFP fragments were PCR-amplified from the
pSpCas9(BB)-2A-GFP vector S1 using respectively the 50- CCAGGGCCCGCTGGGAAGTGGCAAACCGATTCCGAACCCGCTT
CTTGGTCTAGACAGCACCGGTGGCAGTGGAGAGGGCAGA 30 and 50- GTCTGGGGCTACTTGTACAGCTCGTCCATGCC 30
primers, and the 50- CCAGGGCCCGCTGGGAAGTGATTATAAGGATCATGATGGTGACTACAAAGACCATGATATCGATTACAAAGAT
GATGACAAGGGTGGCAGTGGAGAGGGCAGA 30 and 50- GTCTGGGGCTACTTGTACAGCTCGTCCATGCC 30 primers. The
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NEBuilder HiFi DNA Assembly Master Mix (New England Biolabs) following manufacturer’s instructions to generate the pAPOL3-
HRV-V5-2A-GFP or pAPOL3-HRV-TriFlag-2A-GFP tagging constructs respectively. The tagging constructs were linearized using
SalI and KpnI restriction enzymes before use.
Podocytes were transfected usingAPOL3-targeted pSpCas9(BB)-2A-E2Crimson vector and pAPOL3-HRV-V5-2A-GFP vectors to
generate theWT TriFlag, WT 3V5, 1Dhom 3V5 and 1KO 3V5 cell lines. Both induction of cell death and APOL3 expression by poly(I:C)
remained unaltered in the podocyte cell lines expressing V5-tagged APOL3 (see Figures 1B and 1C).
Genomic Analysis of the edited podocytes
Genome libraries were prepared with the Illumina TruSeq Nano DNA HT Sample prep Kit and sequenced on a HiSeq X-Ten platform
with paired-end reads of 150 bp (BGI, Hong Kong). Low quality regions of the reads were trimmed using Trimmomatic v035 (Bolger
et al., 2014). The reads were aligned to the hg38 reference human genomewith the Burrows-Wheeler Aligner (BWA)mem tool v0.7.15
(Bolger et al., 2014; Li, 2013), using default parameters. The resulting sam file was converted to bam, sorted, merged per sample and
indexed with samtools 1.3.1 (Li, 2011). Duplicate reads were marked with the Picard v2.6.0 Mark Duplicates tool and variant calling
was performed with the Genome Analysis Toolkit v3.6-0 Haplotype Caller (GATK) (Van der Auwera et al., 2013). Variants were conse-
quently filtered with the Variant Quality Score Recalibration following exactly the parameters and training sets recommended by
GATK. Finally, variants were annotated with SnpEFF 4.2 (Cingolani et al., 2012). SNPs and INDELs were compared between the
WT podocyte cell line and the CRIPSR/Cas9 mutant cell lines in genome regions with minimal coverage of 10-fold for homozygous
variants and minimal coverage of 20-fold for heterozygous variants.
The genomes of all cell lines were sequenced with at least 26.64-fold average coverage, 97.91% of the genome covered at least
10-fold and 81.58% 20-fold (Table S1B). In total, 3.206.618 SNPs and 864.694 INDELs passed the GATK Variant Quality Score Re-
calibration filter after aligning to the Hg38 reference genome. In a first phase, the genomes of the podocyte cell lines were manually
checked for the CRISPR/Cas9-directed edits in the APOL1 and APOL3 genes (Table S1C). The APOL1KO 1G3, APOL1D 3G3 and
APOL3KOC3 genomes showed homozygous INDELs in the targeted regions of APOL1 or APOL3, and all caused a 100% frameshift.
The APOL1D 3D8 genome had 3 heterozygous INDELs in APOL1, which complemented each other to cause a 100% frameshift. We
additionally checked all the genomes for off-target CRISPR/Cas9 edits to be sure that the observed phenotypes are exclusively
caused by the targeted modifications in APOL1 and APOL3. The off-target SNPs and INDELs are summarized in Tables S1D and
S1E. Only 1 homozygous SNP of moderate impact was detected in the HEG1 (Arg101Ser) gene of the APOL3KO C3 cell line. The
other podocyte cell lines did not contain any homozygous SNPs/INDELs of moderate or high impact. All cell lines did contain het-
erozygous SNPs/INDELs of moderate and high impact. The only two genes showing heterozygous SNPs/INDELs possibly related
with the phenotype, thus, only shared between APOL1D and APOL3KO, were MED1 (Mediator of RNA polymerase II transcription
subunit 1) and POT1 (Protection of telomeres protein 1), two genes for general chromatin organization that are not specifically related
to actomyosin control.
APOL1 inducible cell line
The WT APOL1 addback cell line was generated using TetOne Inducible Expression System (Clontech, Mountain View, USA)
following manufacturer’s instructions. Briefly, APOL1 was PCR-amplified using primers 50-CCCTCGTAAAGAATTCATGTCAGAG
GAAGCTGGAGCGAGG-30 and 50-GCAGAGATCTGGATCCTCACAGTTCTTGGTCCGCCTGCAG-30 and cloned into pTetOne vector
using In-Fusion HD Cloning System (Clontech). The pTetOne vector was transfected into podocytes using Xfect transfection re-
agent (Clontech). Hygromycin resistant cells were screened for APOL1 induction following doxycycline induction.
Generation of G0 and G2 podocyte lines (Figure S12)
Sera analysis
Sera were collected from 19 individuals, and tested for their trypanolytic activity on different Trypanosoma brucei subspecies, as well
as for their APOL1 content (Figure S12A). Sera lytic for T. b. rhodesiensewere also analyzed for the presence of haptoglobin with anti-
human haptoglobin (Dako), (Figure S12B). The primary antibody was detected by anti-rabbit HPR conjugate and ECL substrates
(Perkin Elmer, Waltham, USA). The selected APOL1 G2/G2 genotype carrier sample was number 12. This patient suffered chronic
kidney disease stage 4 post perinatal asphyxia.
APOL1 Genotyping
DNA was extracted from whole blood samples using QIAGEN kits following the manufacturer’s instructions. APOL1 genotyping was
performed for the renal risk allele G2 (6 base-pair deletion, rs71785313). The exon 7 (883 bp) of APOL1 was amplified using gene-
specific primer pairs (Fw50-GTCACTGAGCCAATCTCAGC-30 / Rv50-CATATCTCTCCTGGTGGCTG-30). Subsequently, DNA
sequencing was performed with an ABI 3100XL High-Throughput DNA Sequencer (Applied Biosystems, Foster City, USA).
Cultivation of podocytes exfoliated into urine
Freshly voided urine was collected from the patient carrying APOL1 high risk genotype (G2/G2) and cells exfoliated into urine were
cultured as previously described (Ivanova et al., 2016). In brief, urine was centrifuged at 300 g for 5min, the pellet was washed in PBS
and re-suspended in podocyte growth medium composed of DMEM-HAM’s F-12 (Lonza) with 10% fetal bovine serum (GIBCO),
50 IU/ml penicillin, 50 mg/ml streptomycin (Lonza), 5 mg/ml insulin, 5 mg/ml transferrin and 5 ng/ml selenium (Sigma). Cells were
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human podocytes were infected with retrovirus-containing supernatants from the packaging cell line (PA317). Cells in log-phase
growth were exposed to filtered (0.45 mm) supernatant mixed 1:1 with growth medium plus 8 mg/ml polybrene. After 24 h, cultures
were refed with fresh growth medium and grown for an additional 7 days to confluence. The culture mediumwas then supplemented
with 0.5 mg/ml G418 (Life Technologies BRL, Life Technologies, Paisley, UK) until selection was complete (7 to 10 days). Infection,
selection, and continuous culture were carried out at 33C. Clonal cells were grown at permissive temperature of 33C and, prior to
the experiments, incubated at 37C for 7 days to ensure growth arrest and complete differentiation. APOL1WT podocytes, used as
controls, were generated from a Caucasian patient using the same methodology.
APOL1 sequence of the G2/G2 podocyte cells
The gDNA was isolated from G2/G2 clones and the targeted exon 7 (883 bp) of APOL1 was amplified and sequenced as described
above (Figure S12C).
Immunofluorescence
Immunofluorescence analysis was performed for the podocyte specific proteins synaptopodin, podocalyxin and podocin, as previ-
ously described (Ivanova et al., 2016) (Figure S12D). Briefly, cells grown on glass coverslips were fixedwith 4%paraformaldehyde for
10min at room temperature andwashed once in PBS. Cells were permeabilized in 0.1%Triton X-100 for 5min andwashed twice with
PBS. Blocking solution (0.5% bovine serum albumin, 0.2% gelatin, 0.5% fetal bovine serum in PBS) was added to cells for 20 min
followed by 1 h of incubation with appropriate concentrations of primary antibodies in blocking solution. Cells were washed with PBS
and incubatedwith secondary antibodies (1:1000) diluted in blocking solution. Coverslips were washed in PBS andmounted on glass
slides. Images were acquired using a Zeiss Axio Observer Z1 with a 20x objective.
Analysis of renal biopsies
For each glomerulus the mean level of fluorescence was normalized with respect to the mean level of the control surface. In the case
of WT samples (G0 individuals), two biopsies were analyzed (AP13.1921 and AP13.6775). For the G1 samples the four biopsies were
AP08.4028, AP12.8491, AP15.5049 and AP15.7024, whereas for G2 the biopsy analyzed was AP11.4066.
Apoptosis assays
AnnexinV staining was performed using Annexin V apoptosis detection kit (eBioscience, San Diego, USA) according to manufac-
turer’s instructions. The samples were analyzed by flow cytometry within 30 min.
Cell morphology analysis
Podocytes were grown in 8 wells Falcon culture chamber (Corning, USA) and stained with CellMask Green Plasma Membrane Stain
(ThermoFisher) according to manufacturer’s protocol. Images were acquired using a Zeiss Axio Observer Z1 with a 20x objective.
Cell area and perimeter were quantified with ImageJ.
Cell adhesion assays
Cells were collected using Accutase (Innovative Cell Technologies, San Diego, USA), resuspended at similar density, loaded into hu-
man fibronectin-coated 96-well Microplate (R&D Systems, Mineapolis, USA) and incubated for 1 h at 37C with 5% CO2. The cells
were subsequently washed 5 times with phosphate-buffered saline (PBS) and numbered using CellTiter-Glo Luminescent Cell
Viability Assay (Promega, Madison, USA) following manufacturer’s instructions.
Single cell motility assays
Podocytes were plated in IbiTreat 8 well microslides (Ibidi, Martinsried, Germany) at 103 cells per well dilution and incubated for 10 h
at 37C and 5%CO2 using Zeiss Axio Observer Z1. Imaging was performed using the 10x objective and the automatic heated stage
for live cell imaging. Images were taken from each position of the array every 5 min for 8 h. The individual images from each position
were combined into stacks using ImageJ software. Cell tracking was performed using the MTrackJ plugin (Meijering et al., 2012).
Individual trajectories of 30 randomly selected cells from each group were plotted using Excel software.
Mitochondria analysis
Podocytes were grown in 8 wells Falcon culture chamber (Corning) and stained with MitoTracker Red CMXRos (ThermoFisher) for
30 min at 37C, washed with PBS and fixed for 30 min in 4% paraformaldehyde. Images were acquired using a Zeiss LSM710
confocal scanning microscope with a 40x 1.4NA oil immersion objective. Mitochondria morphology was analyzed using MicroP
and MiNA softwares (Peng et al., 2011; Valente et al., 2017).
Transmission Electron Microscopy
TEM analysis was performed as described (Fontaine et al., 2017). Briefly, cells were fixed for 1h at room temperature in 2.5% glutar-
aldehyde in culture medium, and postfixed in 2% OsO4 in the same buffer. After serial dehydration in increasing ethanol concentra-
tions, samples were embedded in agar 100 (Agar Scientific Ltd., United Kingdom) and left to polymerize for 2 days at 60C. Ultrathin
sections (50 to 70 nm thick) were collected in Formvar-carbon-coated copper grids by using a Leica EM UC6 ultramicrotome ande8 Cell Reports 30, 3821–3836.e1–e13, March 17, 2020
stained with uranyl acetate and lead citrate. Observations were made on a Tecnai10 electron microscope (FEI), and images were
captured with an Olympus VELETA camera and processed with iTEM software (Olympus GMBH, Germany).
Golgi size measurements
On TEM images the Golgi compartment was identified by its unique morphological characteristics. Regions of interest around the
Golgi stacks and the TG network were encircled by the pen tool of the iTEM software (Olympus GMBH) and the integrated perimeter
and surface were automatically calculated.
Western Blot analysis
Cells were lysed in RIPA buffer (1% NP-40 or 1% CHAPS, 0.1% SDS, 0.5% deoxycholate sodium salt in PBS) supplemented with
complete protease inhibitor (Roche, Bale, Switzerland). The protein concentration was determined using BCA protein assay kit
(ThermoFisher). Equivalent amounts of protein were separated on SDS–polyacrylamide pre-cast gels (Biorad, Hercules, USA) and
processed for western blotting.
Immunoprecipitation
Protein lysates in RIPA buffer with 1%NP-40 or 1% CHAPS (300 mg to 1 mg) were incubated with primary antibody overnight at 4C,
followed by incubation with 20 mL of pre-blocked protein G-Sepharose beads for 1 h. Following four washes in RIPA buffer and one
wash in PBS, the immune complexes were eluted in non-reducing Laemmli buffer and analyzed by western blotting. Immunoprecip-
itation of V5- and Flag-tagged protein complexes were performed using anti-V5 Agarose Affinity Gel antibody and anti-Flag M2
Affinity Gel respectively, according to the manufacturer (Sigma).
Immunofluorescence
Cells were grown in Falcon culture chambers (8 wells plate). PBS-washed cells were fixed in 4% paraformaldehyde for 10 min at
room temperature, treated with 0.1% (v/v) Triton X-100 in Tris-buffered saline for 10 min and incubated for 1 h in Tris-buffered saline
with 5% bovine serum albumin. Nuclei were stained with DAPI. PI(4)P and PI(4,5)P2 immunostainings were performed as previously
described (Elong Edimo et al., 2016). Briefly, cells were fixed in formaldehyde 4% and 0.2% glutaraldehyde for 15 min on ice for
PI(4,5)P2 staining or 15 min in 2% PFA et room temperature for PI(4)P staining. After three washes with PBS containing 50 mM
NH4Cl, cells were permeabilized either in buffer A (137 mM NaCl, 2.7 mM KCl, 20 mM PIPES (pH 6.8)) containing 0.1% saponin,
5% normal goat serum (NGS), 5% normal human serum (NHS) for 45 min on ice for PI(4,5)P2 staining or 5 min in buffer A containing
20 mMdigitonin and 45min in PBS NH4Cl, 5%NGS for PI(4)P staining. Anti-PI(4,5)P2 or anti-PI(4)P antibodies were incubated 16 h at
4C. After 3 washes of 5min in PBSNH4Cl, cells were incubated with anti-mouse IgM -Alexa 488 for 1 h at room temperature. Primary
and secondary antibodies were diluted in Buffer A containing 0.1%NGS and 5%NHS for PI(4,5)P2 staining or buffer A containing 5%
NHS for PI(4)P staining. Post-fixation was performed (PFA 2%10min on ice and 5min RT for PI(4,5)P2 staining, 5min in 4%PFA at RT
for PI(4)P staining) and after final washes in PBS NH4Cl cells were mounted. Images were acquired sequentially at each laser exci-
tations wavelength using a LSM710 confocal scanning microscope with a 63x1.4NA oil immersion objective (Zeiss). Co-localization
analysis was performed using JACoP (Just Another Colocalization Plugin) for ImageJ (Bolte and Cordelie`res, 2006). The co-localiza-
tion was quantified using Manders coefficients calculated after Costes automated threshold. Detailed analysis concluded to the val-
idity of this method (Dunn et al., 2011). The extent of focal adhesion foci and Golgi size (expressed as the % of nuclear periphery)
(Dippold et al., 2009) were measured using ImageJ.
Immunogold labeling
For immunogold detection by ultrathin cryosectioning (Tokuyasu), cells were fixed in 4% paraformaldehyde–0.5% glutaraldehyde–
0.1 M cacodylate buffer (pH 7.2) for 15 min at room temperature, embedded in 10% gelatin and 2.3 M sucrose, and frozen in liquid
nitrogen. Sectioning of frozen samples was done on a Leica EM UC7 ultramicrotome at 70 nm. Sections on carbon-Formvar grids
were probed with a rabbit anti-APOL1 antibody and a mix of anti-rabbit IgGs gold conjugates (5 nm and 10 nm) and then mounted
in methylcellulose–1% uranyl acetate films. Observations were made on a Tecnai 10 electron microscope (FEI) at 100 kV and images
were captured with an Olympus VELETA camera and processed with iTEM software (Olympus GMBH, Germany).
Cellular fractionation
Fractionation of podocyte extracts was performed as described (Sibley et al., 1995). Briefly, cells were washed in Hanks’ balanced
salt solution supplemented with 1 mM EGTA and 10 mM HEPES and resuspended at 108 cells/ml in calcium/magnesium-free PBS
containing 1mMEGTA, and then subjected to three freeze-thaw cycles or to sonication for three, 15 s pulses at an intensity of 5 using
a micro-tip probe (Branson Sonifier 185). Protease inhibitors were included in all steps of cell fractionation at the following concen-
trations: 10 mg/ml TLCK, 10 mg/ml a-PMSF, 1 mg/ml leupeptin and 10 mg/ml E-64. Lysates were centrifuged at 2,500 g to remove cell
nuclei and debris. The supernatant was further centrifuged at 100,000 g for 2 h in a TL-100.3 rotor using a Beckman Optima TL
table-top ultra-centrifuge. The membrane pellet was washed once with 1 mM EGTA, 100 mM sucrose, 50 mM Tris-HCl (pH 7.6).Cell Reports 30, 3821–3836.e1–e13, March 17, 2020 e9
Mass spectrometry
Peptides were analyzed by using nano-LC-ESI-MS/MS maXis Impact UHR-TOF (Bruker, Bremen, Germany) coupled with a UPLC
Dionex UltiMate 3000 (Thermo). Lanes were excised from SDS-PAGE gels and proteins were digested with trypsin by in-gel diges-
tion. The gel pieces were washed twice with distilled water and then shrunk with 100% acetonitrile. The proteolytic digestion was
performed by the addition of 6 ml of modified trypsin (Promega) suspended in 50 mM NH4HCO3 cold buffer. Proteolysis was per-
formed overnight at 37C. The supernatant was collected and the eluates were kept at 20C prior to analysis. The digests were
separated by reverse-phase liquid chromatography using a 75 mm x 250 mm reverse phase Thermo column (Acclaim PepMap
100 C18) in an Ultimate 3000 liquid chromatography system. Mobile phase A was 95% of 0.1% formic acid in water and 5% aceto-
nitrile. Mobile phase B was 0.1% formic acid in acetonitrile. The digest (15 ml) was injected, and the organic content of the mobile
phase was increased linearly from 4% B to 35% in 35 min and from 35% B to 90% B in 5min. The column effluent was connected
to a Captive Spray (Bruker). In survey scan, MS spectra were acquired for 0.5 s in the m/z range between 50 and 2200. The 10 most
intense peptides ions 2+ or 3+ were sequenced. The collision-induced dissociation (CID) energy was automatically set according to
mass to charge (m/z) ratio and charge state of the precursor ion. MaXis and Thermo systems were piloted by Compass HyStar 3.2
(Bruker). Peak lists were created using DataAnalysis 4.1 (Bruker) and saved as MGF file for use with ProteinScape 3.1 (Bruker) with
Mascot 2.4 as search engine (Matrix Science). Enzyme specificity was set to trypsin, and the maximum number of missed cleavages
per peptide was set at one. Carbamidomethylation was allowed as fixed modification, oxidation of methionine and Gln- > pyro-Glu
were allowed as variable modifications. Mass tolerance for monoisotopic peptide window was 7 ppm and MS/MS tolerance
window was set to 0.05 Da. The peak lists were searched against the mammalian taxonomy from UNIREF 100. The list of proteins
identified in 1% NP-40 extracts by mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium
via the PRIDE partner repository with the dataset identifier PXD016851 and 10.6019/PXD016851.
In vitro lipid binding assays
Lipid binding assays were performed on lipid-coated strips as described (Wan et al., 2008). Briefly, nitrocellulose membranes pre-
spotted with various indicated lipid species (P-6001, P-6002, Echelon, Salt Lake City, UT) were blocked in 3% fat-free BSA for 60min
at room temperature, probedwith recombinant APOLs (100 ng/ml) in 3% fat-free BSA in TBST for 1 h at room temperature, followed
by primary anti-APOL antibody, secondary goat anti-rabbit antibody conjugated with horseradish peroxidase, and ECL detection
and imaging.
Liposome association assays
Assays were performed by incubating 5 ml of 5 mM liposomes with 2 mg of recombinant protein in a final volume of 50 mL in 0.1 mM
CaCl2, 0.1 mMMgCl2, 30 mM NaCl, 1 mM DTT, 50 mM Tris HCl (pH 7.5). Liposomes were pelleted by centrifugation at 16,000 g for
10 min. Lipid pellets were washed, and supernatant and pellet fractions were analyzed by gel electrophoresis on a 10% polyacryl-
amide gel and processed for western blotting with anti-APOL1 and APOL3 antibodies.
Y2H interaction assays
The Y2H cDNA library construction and screening, and all protein Y2H interaction analyses were performed by Hybrigenics SA (Paris,
France). For interaction analysis, the bait sequence was PCR-amplified and cloned in frame with the LexA DNA binding domain (DBD)
into pB27 as N-terminal fusion (LexA-APOL1Nter). The prey fragments were extracted from the screening of APOL sequences with the
human podocyte library. They were cloned in frame with the Gal4 activation domain as N-terminal fusion into plasmid pP6. The AD
construct was checked by sequencing. Bait and prey constructs were transformed in the yeast haploid cells L40DGal4 (MATa) and
YHGX13 (Y187 ade2-101::loxP-kanMX-loxP, MATa), respectively. The diploid yeast cells were obtained using a mating protocol
with both yeast strains. These assays are based on the HIS3 reporter gene (growth assay without histidine). As negative controls,
the bait plasmid was tested in the presence of empty prey vector (pP7) and the prey plasmid was tested with the empty bait vector
(pB27). The interaction between SMAD and SMURF was used as positive control. Interaction pairs were tested in duplicate as two in-
dependent cloneswere picked for the growth assay. For each interaction, several dilutions of the diploid yeast cells (culture normalized
at 5 3 107 cells) and expressing both bait and prey constructs were spotted on several selective media. The DO-2 selective medium
lacking tryptophan and leucinewas used as a growth control and to verify the presence of both the bait and prey plasmids. The different
dilutionswere also spotted on a selectivemediumwithout tryptophan, leucine and histidine (DO-3). Different concentrations of 3-amino-
1,2,4-triazole (3-AT), an inhibitor of the HIS3 gene product, were added to the DO-3 plates to increase stringency of the interaction.
pDUET assays
Gene co-expression assays in E. coli were performed as described (Lecordier et al., 2009). Cellular lysates usually contained 1%
CHAPS, but in some cases 1% NP-40 was used instead, as indicated. Briefly, cultures of BL21(DE3) strains transfected with
pCDF-Duet1 constructs were grown at 37C in LB containing 50 mg/ml streptomycin and 1% glucose from freshly plated colonies
until OD600 reached 0.7 to 0.8. Cultures were centrifuged and bacteria pellet was resuspended in fresh medium without glucose
and distributed in 3 flasks to perform induction and copurification in triplicate. Expression of recombinant proteins was induced
by addition of 1mM IPTG overnight at 20C and 80 rpm. Cell density was measured by OD600 and bacteria were centrifuged and
resuspended in (10% of culture volume3OD600) in cold hypotonic buffer (50 mMMES pH 6.0 or pH 7.0) containing EDTA-free pro-e10 Cell Reports 30, 3821–3836.e1–e13, March 17, 2020
tease inhibitors (Roche). Bacteria were lysed by Fast Prep 24 (MP Biomedicals) with 1/10 volume of glass beads (LysingMatrix B, MP
Biomedicals), for 33 30 s at 6 m/s. Cell lysate was complemented by 0.6 M NaCl, 1% Triton X-100, 20 mM imidazole, and vortexed
vigorously. Cell debris were pelleted by centrifugation for 15 min at 16,000 g, and the supernatant was applied onto Ni-NTA beads
(QIAGEN) equilibrated in the same buffer, for 2 h at 4C. After binding the beads were washed with 20 volumes of beads with cold
binding buffer and the bound proteins were eluted with 2 volumes of SDS-PAGE sample buffer. Supernatant (total soluble fractions)
and bound fractions were analyzed by western blotting. His tag was revealed with anti-His mouse monoclonal antibody and perox-
ydase conjugated anti-mouse antibody. Stag was detected by anti-Stag monoclonal antibody (Novagen) and peroxydase conju-
gated anti-mouse antibody. Peroxydase activity was revealed by ECL (Western Lighting Chemiluminescence Reagent PLUS, Perkin
Elmer).
N-myristoylated recombinant NCS-1
In order to produce N-myristoylated NCS-1 in E. coli, the gene encoding human N-myristoyltransferase (hsNMT1) was inserted next
to the NCS-1 gene in the pDUET vector, and both proteins were expressed in the presence of myristic acid (Gl€uck et al., 2010; Price
et al., 2012). To check N-myristoylation, the myristate analog 13-tetradecynoic acid (alkynyl myristic acid) was used. E. coli extracts
were incubated with the capture reagent azido-carboxytetramethylrhodamine (TAMRA)-PEG-Biotin (Az-TB), and the TAMRA fluoro-
phore was detected in gels from SDS-PAGE as described in Gl€uck et al. (2010) and Price et al. (2012). Briefly, the hsNMT1 substrate
myristic acid was added 10 min before induction to a final concentration of 50 mM. Myristic acid was supplied as a freshly prepared
5mM stock solution containing 0.6 mMBSA (Sigma). The pH of the stock solution was adjusted with NaOH to 9 and briefly heated to
50C for complete solubilization of myristic acid. Cells were incubated under gentle agitation (150 rpm) and harvested 5 h after in-
duction by centrifugation (5000 3 g, 4C, 30 min). Cell pellets were washed in 1 3 PBS buffer, lysed in ice-cold RIPA buffer
(50 mM Tris pH 7.4, 1% (v/v) NP-40, 1% (w/v) sodium deoxycholate, 150 mM NaCl, 0.5% (w/v) SDS and 1 3 complete protease in-
hibitor cocktail (Roche)), sonicated, then centrifuged at 15,000 g for 30 min at 4C. Samples were separated by SDS-PAGE and the
gel washed briefly in water for in-gel fluorescent imaging. Gels were scanned with Cy3 filters to detect the TAMRA fluorophore.
SPR analysis
All peptides (> 90% pure) were obtained from GenicBio (Shanghaı¨, China). Peptide-peptide interactions were studied by SPR on a
Biacore 3000 (GE Lifesciences, Brøndby Denmark). Peptides were immobilized on a CM5 sensor chip (GE Lifesciences) using
the Thiol Coupling Kit (GE Lifesciences) essentially according to the manufacturer’s instructions. Briefly, peptides containing an
N-terminal cysteine residue (SID2, GC-1, GC-2 and A3-C) were diluted to 50 mg/ml in 10 mM Na phosphate buffer (pH 4.0) and im-
mobilized at surface densities ranging from 0.3 to 1.2 pmol/mm. Binding of SID1 and LZ1 was performed by injecting 40 ml analyte in
concentrations ranging from 0.5 to 80 mM at a flow rate of 10 ml/min in 10 mM HEPES, 150 mM NaCl, 0.05% Tween-20 (pH 7.4) with
either 5 mM EDTA or 50 mM CaCl2. Flow cells were regenerated with two injections of 10 ml 100 mM glycine, 5 mM EDTA, 500 mM
NaCl, 0.05% Tween-20 (pH 3.0) at 10 ml/min. Binding parameters were determined by fitting to a 1:1 interactions model using the
BIAevaluation 4.1.1. (GE Lifesciences). Each parameter was determined by a duplicate run of duplicate factor 2 dilution series of dis-
solved peptide, ranging from 1.25 to 20 mM. As a minimum all experiments were conducted in triplicates of duplicates.
BLI analysis
Data were generated using the Octet RED96e system (Pall ForteBio) at 22C, 1000 rpm orbital sensor agitation in 200 ml volume.
NCS-1 or APOL3 were biotinylated with an EZ-Link NHS-PEG4-biotin (Thermo Fisher) by mixing in ratio 1:3 (protein:biotin) in
10 mM HEPES, 150 mM NaCl (pH 7.4) and incubating for 30 min at room temperature. For all assays streptavidin (SA) biosensors
(Pall ForteBio) were used. Sensors pre-hydrated for 10 min in the BLI running buffer (BLI-RB: 10 mM HEPES, 150 mM NaCl,
50 mM CaCl2, 0.05% Tween 20, 0.1% BSA, pH 7.4) followed by capture of biotinylated NCS-1, myr-NCS-1 (5 mg/ml in BLI-RB) or
APOL3 (20 mg/ml in BLI-RB). Measurements with a loaded biosensor in absence of protein were used as reference and were sub-
tracted from all binding curves. All sensorgrams were aligned using the last 5 s of baseline or second zero of association step. A
Savitzky-Golay filter was applied to smooth the data. All APOL1 and APOL3 proteins were dissolved in 20 mM acetic acid (pH 3).
For BLI measurements proteins were diluted with BLI-RB and the content of 20 mM acetic acid in the prepared sample was adjusted
to be equal in the samples to be compared. For Kd determination, the buffer was 150mMNaCl, 50 mMCaCl2, 0.05% Tween 20, 0.1%
BSA, 10 mM HEPES (pH 7.4). NCS-1 was loaded to 1.2 nm. The baseline was generated in BLI-RB over 300 s. Association with
different concentrations of APOL3 (diluted in BLI-RB) was measured for 1200 s, and dissociation in BLI-RB was measured as well
over 1200 s. Sensors were regenerated in 10 mM NaOH (pH 10), three times for 5 s. The sensorgrams were aligned using the last
5 s of baseline, fitted using 1:1 binding model (ForteBio Data Analysis 10.0 software), analyzing both association and dissociation.
Binding curves were analyzed using Global (Full) fit with Rmax unlinked by sensor. R2 was always above 0.99 and X2 was lower
than 0.65. The Kd was determined as an average of three experiments. For the binding of APOL1 variants/APOL3 to NCS-1 or
APOL3, the buffer used was 100 mM NaCl, 50 mM CaCl2, 0.05% Tween 20, 0.1% BSA, 200 mM HEPES (pH 7.4). The loading of
NCS-1 was to 1.2 nm or APOL3 to 0.7-1 nm. The baseline was generated in BLI-RB over 120 s. Association with 0.2 mM APOL1,
APOL1D, G1, G2, APOL1D1, APOL1 LZ1mut or APOL3 diluted in BLI-RB was measured for 600 s and dissociation in BLI-RB was
measured as well over 600 s. In another experiment a mixture of 0.2 mM APOL3 and APOL1 variants in different molar ratios (1:1,
1:3 or 1:5) was used for association. For the binding of APOL3 to NCS-1 ± CHAPS, NP-40 or TWEEN 20, the buffer used wasCell Reports 30, 3821–3836.e1–e13, March 17, 2020 e11
150mMNaCl, 50 mMCaCl2, 0.1%BSA, 10mMHEPES (pH 7.4) ± 1%CHAPS, 1%NP-40 or 0.05%TWEEN 20. NCS-1 was loaded to
1 nm and the baseline generated in BLI-RB containing 1% CHAPS, 1% NP-40 or 0.05% TWEEN 20 over 300 s. Association with
0.2 mM APOL3 diluted in BLI-RB containing 1% CHAPS, 1% NP-40 or 0.05% TWEEN 20 was measured for 1000 s and dissociation
in BLI-RBwasmeasured as well over 1000 s. For the Ca2+-dependent binding of APOL3 to NCS-1, the buffer used was 150mMNaCl
(CaCl2 free), 10 mM EGTA, 0.05% Tween 20, 0.1%BSA, 10 mMHEPES (pH 7.4). This buffer was used as a basic buffer and different
amounts of CaCl2 were added to achieve certain concentrations of free Ca
2+ based on the MaxChelator Ca-EGTA Calculator v1.3
(Schoenmakers et al., 1992) using the following settings T = 22C, 0.01 M EGTA, 0.15 N ionic strength (pH 7.4). NCS-1 was loaded
to 1 nm and sensors were calibrated for 10min in basic buffer before the measurements were started. The baseline was generated in
corresponding buffers (±CaCl2) over 600 s and association of 0.2 mM APOL3 over 600 s.
For the competition assay of NCS-1 mutant for binding to APOL3, the buffer used was 150 mMNaCl, 50 mMCaCl2, 0.05% Tween
20, 0.1%BSA, 10 mMHEPES (pH 7.4). NCS-1 was loaded to 1-1.2 nm and the baseline generated in BLI-RB over 120 s. Association
with 0.2 mMAPOL3 (diluted in BLI RB) or 0.2 mMAPOL3mixed with 0.4 mMNCS-1WT or mutant wasmeasured for 1000 s, and disso-
ciation in BLI RB was measured as well over 1000s. For the binding of PI4KB and/or APOL3 to (N-myristoylated-) NCS-1, the buffer
used was 150 mMNaCl, 50 mMCaCl2, 1%CHAPS, 0.1%BSA, 10 mMHEPES (pH 7.4). The loading of NCS-1 or myr-NCS-1 (5 mg/ml
in BLI-RB) was to 1.5-1.8 nm. The baseline was generated in BLI-RB over 60 s. Association with 0.1 mMAPOL3 (diluted in BLI RB) or
0.1 mM APOL3 mixed with 0.1 mM PI4KB or 0.1 mM PI4KB (Thermo) alone was measured for 1000 s, and dissociation in BLI RB was
measured as well over 1000 s. After this first dissociation there was a second association step with 0.1 mMAPOL3 or 0.1 mMPI4KB in
BLI RB over 1000 s followed by a second dissociation. For the binding of APOL1 or APOL1D to NCS-1 or NCS-1-APOL3 complex, the
buffer used was 150 mM NaCl, 50 mM CaCl2, 0.05% Tween 20, 0.1% BSA, 10 mM HEPES (pH 7.4). NCS-1 was loaded to 1 nm and
the baseline generated in BLI-RB over 120 s. Association with 0.2 mM APOL3, APOL1 or APOL1D, diluted in BLI RB, was measured
for 1000 s, followed by a second association of the same proteins in another order was measured over 1000 s.
Nile red-based hydrophobicity assay
In order to remove protein aggregates, recombinant APOL1, G1 or G2 were filtered and quantified directly after filtration using Nano-
drop spectrometry. Concentrations were set at 1 mM in 20 mM acetic acid and directly mixed with the hydrophobic dye Nile red
(Sigma-Aldrich) (0.01 mM in dimethyl sulfoxide). Fluorescence was monitored with a Nano Synergy Mx microplate reader with
550 nm and 630 nm as the excitation and emission wavelengths, respectively.
APOL1 variant quantification by qRT-PCR
Total RNAwas purified using Direct-zol RNA kit from Zymo Research. The reverse transcription reaction was performed using 1 mg of
total RNA with the PrimeScript RT reagent Kit with gDNA Eraser, both from Takara. The qPCR reaction was performed with SYBR
Premix Ex TaqII (Tli RNaseH Plus) from Takara. The cycling conditions were as following: 30 s at 95C, then 40 cycles alternating 5 s at
95C and 30 s at 62C, then 15 s at 95C. This amplification stage was followed by a melting curve. The sequences of the primers
used to amplify APOL1 variants are the following: APOL1 Ex2-Forward: 50-CCAGCTTTGCAATCATGAGATTC-30, APOL1
Ex4 Reverse: 50-TTCCTCTGCCCTCACTCC-30, APOL1 Ex3-Forward:50-ATGGAGGGAGCTGCTTTG-30, APOL1 Ex 3-5 Forward:
50-TGCATCTGGGTGCAACAAA-30, APOL1 Ex5-Reverse: 50-GATACTGCTCTCTGGGTCCAT-30. Variant 2 was amplified using pri-
mersAPOL1 Ex2-Forward and APOL1 Ex4 Reverse, variants 1 + 2 using primersAPOL1 Ex3-Forward and Ex4 Reverse, variant 3
using APOL1 Ex 3-5 Forward and APOL1 Ex5-Reverse, and all variants using APOL1 Ex3-Forward and APOL1 Ex5-Reverse. The
relative incidence of each variant was calculated as described (Camacho London˜o and Philipp, 2016).
Trypanolysis assays
In vitro measurements of APOL trypanolytic activity were performed as described (Fontaine et al., 2017; Lecordier et al., 2015).
Briefly, trypanosomes were incubated at 5.105/ml in HMI-9 supplemented medium at 37C in a CO2-equilibrated incubator. At the
indicated times, living trypanosomes were counted in triplicate under the microscope. In these assays the volume of the APOL sam-
ples, in 20 mM acetic acid (pH 5), was kept constant so that there was no difference of acetic acid content between samples.
Normalizations were performed to untreated controls.
PI4KB activity measurements
PI4KB activity was measured in an in vitro assay based on bioluminescent detection of ADP, as described (Tai et al., 2011). Briefly,
recombinant PI4KB, APOL1, APOL3 and NCS-1 were diluted in 96 well-plates in kinase buffer (50mM NaCl, 2 mM MgCl2, 25 mg/ml
BSA, 0.04% Triton X-100, 50 mMDTT, 4 mMMnCl2, 100 mMHEPES pH 7.5) containing either 0.5 mM EGTA, 0.1 mM CaCl2 or 2 mM
CaCl2. After preincubation for 10 min at room temperature, the PI4KB substrate (PI:PS mix) was added. Reaction was started by
addition of 40 mM ATP and incubated for 40 min at 30C. ADP was revealed by ADP-Glo kinase assay kit (Promega) following man-
ufacturer’s instruction. Background activity was evaluated by omission of either IP substrate, ATP or PI4KB, and was always lower
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Electrophysiology of APOL3
Planar lipid bilayers were formed by folding two lipid monolayers over a hole (110-150 mm in diameter) made in a 25 mm thick Teflon
partition that separated two Teflon experimental chambers as described previously (Mlayeh et al., 2010). Briefly, the bilayer was
made of either soybean phospholipid or 50% DOPC / 45% DOPE / 5% PI(4)P (w/w), purchased from Avanti. Lipids were dissolved
in hexane to a final concentration of 2% (w/v). Ag/AgCl electrodes connected in series with a salt bridge (1M KCl in 1% agar) were
used to connect the experimental chambers to the electronic equipment. The trans compartment was defined as the one connected
to the ground (reference) and the voltage was applied to the cis compartment. For channel reconstitution into a planar lipid bilayer,
recombinant APOL3 was added to the cis compartment (final concentration 400 ng/ml). All solutions were buffered with 10 mM
HEPES (pH 7.5). Current recordings were performed using a BLM 120 amplifier (BioLogic, France). Data were filtered at 300Hz
(5-poles linearized Tchebichev filter) and digitized at 44.1 kHz. The reversal potential (zero-current potential) was set to zero in pres-
ence of 1MKCl on both sides of themembrane. The cis compartment was afterward perfused three times its volumewith a solution of
0.1 M KCl and the change in reversal potential (Erev) was recorded. The values of Erev were corrected for the liquid junction potential
at salt bridges. The ideal selectivity toward monovalent cations is given by the Nernst equation: Erev = 59.1 3 log10 (a trans / a cis),
where ‘a’ is the activity of the solution.
Cytosolic Ca2+ measurement
Cytosolic Ca2+ levels were monitored with Fura-2 AM as previously described (Bittremieux et al., 2017). Briefly, measurements were
performed by seeding the different podocyte cell lines at 40,000 cells per well in 96-well plates (mclear, Greiner Bio-one). After dif-
ferentiation as described above, the cells were loaded for 30 min with 1.25 mM Fura-2 AM at room temperature in modified Krebs
solution containing 150 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 11.5 mM glucose, 1.5 mM CaCl2 and 11.6 mM HEPES (pH 7.3), fol-
lowed by a de-esterification step of 30 min in the absence of Fura-2 AM. Fluorescence was monitored on a FlexStation 3 microplate
reader (Molecular Devices, Sunnyvale, CA, USA) by alternately exciting the Ca2+ indicator at 340 and 380 nm and collecting emitted
fluorescence at 510 nm. For the dose-response experiments, EGTA (final concentration 3 mM) and increasing concentration of ATP
(final concentration 0.3 up to 100 mM) were added. Ca2+ release from ER and non-ER stores (Golgi) was assessed by adding respec-
tively EGTA (3mM final concentration), thapsigargin (500 nM final concentration) and finally ionomycin (10 mM final concentration). All
traces are shown as the ratio of emitted fluorescence of Fura-2 (F340/F380) after a background correction. Concentration-response
relationships were fitted to an asymmetric sigmoidal, five-parameter dose-response curve, which derives 50% efficient concentra-
tions (EC50) (GraphPad Prism software).
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed using Prism software (GraphPad). Immunofluorescence data were obtained from randomly
selected cells from three independent experiments, and the images shown are representative of the majority of cells. Quantitative
data were represented as means ± standard deviation (SD); n = 3 unless otherwise indicated in the figure legends; no sample
was excluded. Normality of the data was analyzed with the Shapiro-Wilk test. p values were calculated by the Student’s t test
and one-way ANOVA (post hoc Dunnett’s test), for multiple and single comparisons of normally distributed data respectively, and
by the Kruskal–Wallis (post hoc Dunn’s test) for multiple comparisons of non-normally distributed data (*p < 0.05; **p < 0.01;
***p < 0.001; ****p < 0.0001).
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